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Abstract 
 Engineering Therapeutic Biomaterials for Medical Implants 
Yiqi Cao 
Understanding material-host interactions is critical to designing and characterizing 
biomaterials for use in medical implants. From joint replacements, to pacemakers, to artificial 
hearts, all surfaces that contact the body require thorough characterization and optimization to 
elicit an appropriate response in the body. This dissertation discusses the applications of 
biomaterials for two distinct clinical needs: ocular drug delivery, and vascular stenting.  
The first half of this dissertation discusses the surface engineering of titanium implants 
by fabricating TiO2 nanotube coatings. First, Chapter 1 provides an overview of the uses of TiO2 
nanotubes for applications in tissue engineering, smart drug release platforms, and biosensing. 
Then, Chapter 2 is a mechanistic study of titania nanotube topography as a surface coating for 
vascular stents. In this study, we investigated how nanotopographical cues on the stent surface 
can modulate vascular phenotype, with the goal of developing an alternative strategy to drug-
eluting stents (DES) for decreasing restenosis. We demonstrated that nanotube topography can 
decrease SMC surface coverage without affecting endothelialization. In addition, to our 
knowledge, this is the first study reporting that TiO2 nanotube topography dampens the response 
to inflammatory cytokine stimulation in endothelial and smooth muscle cells. 
The second part of this work addresses the clinical need for long-acting intraocular drug 
delivery implants. Chapter 3 is a survey of recent advances in long-acting, sustained-release 
intraocular implants, highlighting the recent developments spanning the pre-clinical, clinical, and 
post-FDA approval stages. Then, Chapter 4 is a report of the design, characterization, and in vivo 
validation of a drug delivery implant for the treatment of glaucoma. Eye drop administration is 
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the current gold standard, but patient noncompliance is an obstacle to efficacious treatment. We 
designed a polymeric implant to co-deliver two hypotensive agents, achieving independently 
controlled zero-order release of timolol maleate and brimonidine tartrate. We also demonstrated 
IOP-lowering effects of the implant for three months in vivo. Taken together, these projects seek 
to contribute to the continued expansion and development of the biomaterials field and its 
applications in medicine. 
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TiO2 nanotube arrays as smart platforms for biomedical applications 
 
1.1 Abstract 
TiO2 nanotube arrays (NTAs) have met increasing interest in the scientific community due 
to their extraordinary properties, including responsivity to UV light and biocompatibility. These 
properties have motivated their application in many fields ranging from energy to environmental 
remediation and regenerative medicine. This chapter briefly reports on their most recent 
biomedical applications by citing significant examples of works that exploit TiO2 NTAs, alone or 
in association with other nanomaterials, for remote control through many physical sources. In 
particular, the focus is on TiO2 NTAs as active devices for interaction with biological 
environments in tissue engineering, drug delivery and biosensing. 
 
1.2 Introduction 
Titanium is a material extensively used for many biomedical applications due to its 
corrosion resistance, light weight, and biocompatibility. Recent advances in nanotechnology have 
offered significant opportunities to tune surface features by development of several kinds of 
nanostructures, most notably TiO2 nanotubes. 
Over the last two decades, many straightforward and inexpensive fabrication methods have 
been developed, including hydrothermal and electrochemical synthesis [1, 2, 3]. By simple 
variations of fabrication parameters such as electrolyte composition, reaction temperature and 
anodization voltage, these methods enable the formation of TiO2 nanotube arrays (TiO2 NTAs) 
with different characteristics such as length, diameter, density, wall thickness etc. Nanotube 
surface morphology can be easily improved, for instance, by ultrasonication procedures at the end 
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of the fabrication process, or even by sequential anodizations [4, 5]. Typical products of 
electrochemical anodization are amorphous nanotubes, which can be later converted into 
crystalline materials by thermal treatment, with improvement in nanotube purity [6]. Annealing 
temperature and nanotube diameter are critical in obtaining anatase TiO2 (300-500°C), rutile TiO2 
(above 500°C), or combinations thereof, all characterized by different conductivity properties (in 
the 10-1 Ω cm range for anatase, and 102 Ω cm for rutile). Moreover, if amorphous nanotubes 
exhibit a band gap of ~3.3 eV, anatase ones have a band gap of 3.2, whereas rutile nanotubes have 
an even narrower band gap of 3.0 eV. These crucial properties are at the base for the application 
of TiO2 NTAs as smart materials for many biomedical applications. In these semiconductors 
sensitive to UV light, electrons promoted from the valence band to the conduction band can reach 
the material interface, where they react with environmental redox species [1]. Generation of highly 
reactive species occurs and results in oxidation of biomolecules, with important microbial control 
effects [7]. 
In this chapter, studies on the application of TiO2 NTAs to tissue engineering, drug delivery 
and biosensing are presented. When possible, focus will be on the “smart” properties of these 
materials, and thus on the tunability of their effects on biological environments through remote 
control. The auspice is to stimulate the discussion on these fascinating materials in the scientific 
community, and to open novel pathways for challenging biomedical applications of TiO2 NTAs. 
 
1.3 Tissue engineering based on TiO2 nanotube arrays 
Nanostructured materials are increasingly used in biomedical research in order to modulate 
biological responses and eventually direct cellular behavior towards a desired phenotype [3, 8, 9]. 
The ultimate goal is often the faster recovery of structural and functional integrity in tissues 
compromised by degenerative conditions of disparate etiology, including trauma. Interest in TiO2 
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NTAs for affecting cell response and influencing cell fate is largely due to the possibility to tune 
their geometry and composition by straightforward adjustments of fabrication parameters. Among 
these, anodization voltage can for instance be easily changed to produce arrays of nanotubes with 
strikingly different diameters, wall thicknesses and lengths. 
Over the latest two decades, several in vitro studies have focused on the interaction of TiO2 
NTAs with different kinds of cells, such as chondrocytes [10], endothelial cells [11, 12], smooth 
muscle cells [11], macrophages [13], mesenchymal stem cells [8, 14, 15, 16], neural progenitors 
[17], osteoblasts [18], periodontal ligament stem cells [19], platelets and leucocytes [20]. Most 
studies have investigated the biological effects of nanotube diameter, often in association with 
nanotube chemistry (by doping during fabrication/annealing, or by modification with wet 
chemistry and plasmochemical routes). Only recently, there have been studies that exploit TiO2 
NTAs as active devices for delivering physical stimulation to cells and tissues. In the following, a 
few significant examples of both approaches will be discussed, implying future perspectives for 
these versatile nanomaterials. 
 Relevant studies on the potential of TiO2 NTAs to influence cell behavior have been 
conducted since 2007 [8, 10, 14, 15, 18, 21]. These works have demonstrated the critical role of 
urface topography in influencing events like adhesion, apoptosis, proliferation and even 
differentiation, and have suggested how the surface chemistry may synergistically rather than 
additively work to affect specific biological responses.  
For instance, Tejal Desai’s group investigated the effects of long-term interaction of arrays 
of 80 nm diameter nanotubes with rat mesenchymal stem cell (MSCs), finding enhanced alkaline 
phosphatase activity and calcium content in the cultures. No adverse immune response was 
detected after subcutaneous implantation of TiO2 NTAs in a healthy murine model [15]. 
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Furthermore, TiO2 NTAs were demonstrated to be substrates suitable for decreased adhesion of 
Staphylococcus epidermidis and for MC3T3-E1 pre-osteoblast differentiation after nanotubes 
were loaded with gentamycin [21]. In another study, arrays of TiO2 nanotubes with 30 nm diameter 
were found to be improving bovine aortic endothelial cell (EC) proliferation, while maintaining 
mouse aortic smooth muscle cell in their differentiated status. Also, ECs secreted more 
prostaglandin I2 on TiO2 NTAs compared to flat titanium surfaces, thus demonstrating suitability 
of the array for coating of vascular stents [11]. Based on these findings, whole genome analysis 
was performed on the cultures, and confirmed again this divergent behavior of ECs and SMCs 
with respect to proliferation and migration [22]. Further, the study demonstrated that TiO2 NTAs 
led to downregulation of genes involved in inflammation and coagulation, processes related to 
restenosis and thrombosis in both cell types. 
A study from Park and coworkers provides a good example of investigation of the 
biological effects of array topography and chemistry. In this study, arrays of TiO2 nanotubes with 
15 nm and 100 nm diameter were used for MSC culture either in the presence or in the absence of 
bone morphogenetic protein-2 (BMP-2), a growth factor stimulating both chondro- and osteogenic 
differentiation [10]. Chondrogenic differentiation of MSCs was enhanced by BMP-2 coated 
nanotubes of 100 nm in diameter, but not on coated 15 nm diameter nanotubes, where spreading 
and de-differentiation occurred. Conversely, osteogenic differentiation was promoted by BMP-2 
coated 15 nm diameter nanotubes, but not by 100 nm diameter nanotubes. Coating with BMP-2 
was also effective at preventing apoptosis found on 100 nm diameter nanotubes. The observed 
differences in MSC behavior on arrays of TiO2 nanotubes with different diameter were ascribed 
to integrin clustering. 
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TiO2 NTAs-coated devices also interact with soft tissues. In a pilot investigation, TiO2 
NTAs were tested with C2C12 myoblasts, aiming at skeletal muscle tissue engineering and 
stimulation [6]. Arrays with increasing nanotube diameters were fabricated and annealed to anatase; 
then, they were either coated with laminin or not, and used for supporting both cell proliferation 
and differentiation. The synergic effect of surface topography and chemistry was demonstrated, 
pointing to laminin-coated arrays with 10 nm diameter nanotubes as the most beneficial substrates 
for myoblast adhesion and differentiation. 
In another study, plain arrays of TiO2 nanotubes with 100 nm diameter were tested for 
implantation in rat abdominal wall, where they significantly reduced fibrotic capsule formation 
and exerted a more pronounced nitric oxide scavenging activity in comparison to planar titanium 
surfaces [23]. Recent studies conducted on vascular titanium stents coated with 100 nm diameter 
TiO2 nanotubes confirmed that the coating improved long term stent integration in the iliofemoral 
artery of a rabbit model by decreasing neointima formation and accelerating recovery of functional 
endothelium. This resulted in a 30% lower in-stent restenosis compared to controls, and promises 
application of TiO2 NTAs in drug-free vasculature prosthetics [24]. 
A very recent study from Park and coworkers proposes the use of 15 nm diameter TiO2 
NTAs for promoting osteodifferentiation of MSCs by electric field (EF) stimulation, in the absence 
of pro-differentiative soluble factors [25]. In this study, a low voltage was applied to the arrays, 
which served as anodal electrodes during long-term electric field stimulation. EF application 
increased Ca2+ levels and connexin 43 (Cx43) localization at the plasma membrane protrusions. It 
also determined intercellular spreading of Ca2+ fluxes through gap junctions, that resulted in 
downstream signaling activation (including calcineurin/CAMKII phosphorylation and NFAT 
dephosphorylation). Overexpression of osteogenic differentiation markers like osteocalcin and 
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osterix was found at a transcriptional and translational level, as well as enhanced mineralization 
upon EF application to TiO2 NTAs. The latter were therefore found suitable to electric field 
application for osteodifferentiation induction. 
As suggested by the studies presented above, the role of TiO2 nanotube diameter in arrays 
for tissue engineering is well recognized and to date is still the focus of intense debate. This field 
is growing in breadth due to innovative methods for enriching array properties during synthesis by 
doping, or at fabrication endpoint by surface modification with other nanoparticles and functional 
groups of biological relevance [3, 26]. Investigations on array features such as crystallinity and 
related conductivity may provide further advances in tissue engineering applications of TiO2 NTAs 
in the near future, eventually turning them from passive vehicles of bioinstructive cues to 
intrinsically active and multifunctional interfaces (microbial control, electrical stimulation, etc.) 
for dynamic, tunable interaction with biological environments. 
 
1.4 Drug delivery from TiO2 nanotube arrays 
Drug-releasing implants represent a promising strategy for achieving therapeutic 
concentrations of drugs to a target site with minimal or no systemic effects. Titanium is a material 
of common use for implants, due to its biocompatibility and mechanical stability, and provides a 
resistant platform for shape and surface modifications. Indeed, titanium medical devices can be 
surface-coated with vertically aligned nanotube arrays for drug loading and release, including bone 
screws [27], titanium stents [24], and wires [28, 29]. The main advantages provided by TiO2 
nanotube arrays (NTAs) are their simple and inexpensive fabrication procedures (for instance, 
through electrochemistry), and their tunable features (length, diameter, conductivity, etc.) [1, 29, 
30, 31, 32]. These properties have motivated many orthopedics, dental, and vascular surgery 
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applications [11, 25, 33, 34]. In the following section, relevant properties of TiO2 NTAs will be 
briefly recalled and examples of studies exploiting the extraordinary properties of these materials 
as smart platforms for drug delivery purposes will be reported. 
The kinetics of drug release from plain TiO2 nanotubes is based on desorption and diffusion. 
Drug release depends on factors including nanotube surface chemistry, surface area and pore size, 
along with molecule size, charge, drug solubility, and diffusion coefficient. The Desai group 
fabricated nanotubes with varying heights and diameters to explore the release rates of model 
proteins (albumin and lysozyme) and antibiotics (sirolimus and paclitaxel) [34, 35], changing from 
burst release, where the majority of drug is eluted in a few hours, to prolonged release over a week. 
To achieve prolonged release profiles, recent studies proposed biodegradable films for nanotube 
capping [36, 37], and polymeric micelles for drug encapsulation [38]. Other studies focused on the 
photocatalytic properties of the nanotubes for drug release modulation, aiming at turning TiO2 
NTAs into active “smart” devices. Indeed, TiO2 nanotubes are semiconductors with photocatalytic 
properties so they are able to induce redox reactions when irradiated by light of suitable 
wavelength [39]. This peculiar characteristic of TiO2 NTAs has also been exploited in association 
with properties of other nanomaterials, thus making drug delivery devices based on TiO2 NTAs 
responsive to many external stimuli, including magnetic fields, radiofrequencies and ultrasounds. 
Among the first studies on light-induced drug release from TiO2 NTAs, there is that one 
from Song and coworkers. TiO2 NTAs were coated with (3-aminopropyl)triethoxysilane, APTES, 
a siloxane linker, then loaded with horseradish peroxidase, a model drug, and with 
octadecylphosphonic acid (ODPA) for nanotube capping. Amphiphilic drug release platforms 
were obtained by two sequential anodizations [4]. Upon UV-light irradiation, the ODPA cap 
underwent UV-induced chain scission, which exposed the loaded drug and allowed its diffusion 
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into the aqueous environment. The APTES linker also underwent UV-induced chain scission, thus 
contributing to controlled drug release after irradiation. In another study, a fluorescent molecule 
was used as a model drug, and was attached to TiO2 nanotubes using a siloxane cross-linker. Upon 
illumination by UV light, hole generation in the valance band of the titanium oxide led to chain 
scission of the siloxane linker, triggering drug release from the nanotubes. This platform was also 
compatible with magnetic nanoparticle filling, so that the location of the implant could be 
controlled by application of a static magnetic field [40]. 
To overcome limitations inherent to UV light irradiation, including payload degradation or 
poor tissue penetration in vivo, hybrid drug delivery systems based on TiO2 NTAs were developed 
to allow drug release upon exposure to visible or infrared light. An interesting example of drug 
release induced by visible light is represented by a study on a dual device, where the first nanotube 
layer was used for capping and the second one for antibacterial drug loading through silane. The 
first layer was decorated with gold nanoparticles (Au NPs), and it was then coated with a 
hydrophobic cap. By visible light irradiation, gold surface plasmon resonance occurred that 
photocatalytically induced chain scission of the cap. This resulted in silane degradation along with 
sustained ampicillin release. Antibacterial effect of the device was also demonstrated on 
Escherichia coli cultures [41]. 
On-demand drug release systems using TiO2 NTAs have also been demonstrated with near 
infrared light, which has the additional advantage of higher tissue penetration (1-2 cm under the 
skin). In order to make devices responsive to infrared light, gold nanorods (GNRs) were grafted 
onto TiO2 nanotubes via thiolactic acid treatment by Moon and coworkers [42]. Tetracycline, an 
antibiotic, was then loaded into TiO2 nanotubes. GNRs exhibited photothermal effects upon IR-
irradiation, leading to a local heating effect that increased drug diffusion. The photothermal effect 
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was shown to increase the release of tetracycline from the arrays, which exerted antibacterial 
effects on Streptococcus mutans cultures. 
The association of TiO2 NTAs with gold nanomaterials also enables drug release upon 
local heating induction by radiofrequency. In a study from Bariana and coworkers, nanotubes 
anodized on the surfaces of a titanium wire were loaded with AuNPs, and coated by tocopheryl-
poly(ethylene glycol)-succinate micelles for release of indomethacin, an anti-inflammatory drug 
[43]. Radiofrequency (RF) stimulation of different durations modulated payload release after 
immersion in saline solution. A release of 80-100% of the drug was obtained by a short-term RF 
stimulation at 20W for 5 min, achieving a dosage of 100-250 µg (much higher that that allowed 
by oral administration). This study shows promise for enabling non-invasive, on-demand release 
of high drug dosages. 
 TiO2 NTAs provide an excellent platform for remote controlled drug delivery also through 
magnetic field upon combination with magnetic nanoparticles. In a study from Aw and coworkers, 
magnetic iron oxide nanoparticles coated with dopamine were loaded into titanium nanotubes, 
followed by indomethacin-loaded micelles [44]. Without magnetic stimulation, drug release 
exhibited near zero-order kinetics, as expected from drug release out of micelles. When a magnetic 
field was applied, the magnetic particles were dragged out of the tubes, allowing 100% drug release 
within 1-1.5 h. 
In another study from Aw and coworkers, TiO2 nanotubes were again loaded with drug-
encapsulated polymeric micelles, but drug release was triggered with the aid of ultrasounds (US) 
[45]. Different US parameters (including pulse length, time, amplitude, and power intensity) were 
finely explored to trigger the release of micelles from the nanotubes. Optimal stimulation led to 
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100% drug release within 5-50 min from US application, very likely due to processes including 
cavitation and temperature increase that deserve further studies. 
TiO2 nanotube arrays are promising surface coatings for drug-eluting implants. These 
nanostructures can be obtained on existing titanium implants through a simple and inexpensive 
process. TiO2 nanotubes can serve as reservoirs for small molecule and protein therapeutics, as 
well as drug-encapsulating micelles, for achieving desired rates of drug release. Thanks to the 
inherent smart properties of TiO2 nanotube arrays themselves or arising upon interaction with other 
nanomaterials, these devices demonstrate on-demand drug release in response to an external 
trigger, such as light, radiofrequency, magnetic field, and ultrasounds. While many of these 
platforms still require further in vivo validation, they are promising for local, controlled drug 
delivery in many applications ranging from orthopedics to cancer treatment. 
 
1.5 Biosensing mediated by TiO2 nanotube arrays 
Titanium dioxide nanotube arrays (TiO2 NTAs) represent excellent substrates for the 
quantification of several typologies of biomolecules, by working as probe-free analytical devices, 
or as immobilization platforms of biorecognition elements. In most applications, they mediate the 
detection of events involving antibodies [46, 47], antioxidants [48, 49], metabolites [51, 52, 53, 
54, 55, 56, 57], neurotransmitters [58], peptides/proteins (regulatory [59, 60], or not [61]), and 
even xenobiotics [62]. The extraordinary physical properties of TiO2 NAs can be exploited per se 
[46], or they can be improved by association to low-cost metal nanoparticles, such as Cu2O [55], 
or to noble metal nanoparticles, such as Ag [63], Au [49, 53, 54, 56, 61, 64], Pt [57] and 
combinations thereof [52]. Over the last two decades, TiO2 NAs have been used for quantification 
of analytes mainly through amperometric methodologies [48, 51, 52, 54, 63] and by taking 
advantage of their intrinsic photocatalytic properties [56, 57, 58, 60, 61, 62, 63]. Other techniques 
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have also been used, including immunochemistry [47, 53], interferometry [46], and spectroscopy 
[56, 57, 60], providing increasing evidences of the high versatility of TiO2 nanotube arrays even 
in biosensing applications. 
The main reasons for the continued interest in TiO2 NTAs lie in their simple and 
inexpensive fabrication procedures, in their photocatalytic properties (exhibited over a wide active 
surface), their facile tunability by doping/surface decoration (see for instance [63]), and in their 
high biocompatibility, that enables the full retention of the biological activity of biorecognition 
elements also after immobilization. Indeed, chemical reactions can occur at the nanoscale on the 
nanotube surface and even within nanotube channels, deeply affecting biosensing outcomes. 
Moreover, TiO2 NTAs are semiconductors where electrons can be promoted from the valence band 
to the conduction band by light (typically UV) of energy higher than the band-gap (3 eV for rutile 
and 3.2 eV for anatase), thus generating holes in the valence band. Electrons and holes can react 
with environmental acceptor and donor species, thus allowing analyte quantification upon 
photocurrent determination. Arrays of TiO2 nanotubes possess high electron conduction properties 
that can be enhanced when an external electric field is applied. The latter can promote deposition 
of metal nanoparticles on the array surface, resulting in efficient electron transfer due to improved 
charge separation. TiO2 NTAs provide electron percolation pathways, show large capacitance in 
solution, and have defined, controllable reflectance spectra [1, 2]. 
Biosensors based on the simple electron conductivity of TiO2 nanotube arrays have been 
proposed for the quantification of glucose [51, 54, 55], hydrogen peroxide [50, 52, 53, 55], ascorbic 
acid [48], glutathione [49] and immunoglobulin G [46]. Of the cited examples of TiO2 NTA-based 
devices, only biosensors that were reported to have very high performances in terms of detection 
limit, sensitivity, response time and analytic range will be concisely presented in the following. 
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Among the studies on photoelectrochemical biosensors, there is that one performed by An 
and coworkers on α-synuclein [61]. In this study, TiO2 NTAs were obtained by electrochemistry, 
photoelectrochemically decorated by Au nanoparticles (Au NPs) and then with primary antibodies 
against α-synuclein. Complexes of Au NPs with secondary antibodies and with glucose oxidase 
were also immobilized on the surface for signal amplification. In the presence of glucose, the 
enzyme produced hydrogen peroxide, which acted as a sacrificial electron donor for scavenging 
of UV light-generated holes in the valence band of the arrays, thus improving charge separation. 
Higher photocurrents were obtained when the arrays were decorated by Au NPs on both sides. The 
obtained immunosensor exhibited linear response in the 50 pg/ml - 100 µg/ml analyte range, and 
a detection limit of 34 pg/ml, denoting high sensitivity. 
Biosensors that are molecularly imprinted with the analyte can provide enhanced 
sensitivity and photocurrents due to improved electron transfer. In a study from Wang and 
coworkers, this was shown for the quantification of a pesticide, chlorphyrifos [62]. In this study, 
TiO2 NTAs were electrochemically obtained and decorated with Au NPs, and then coated with 
poly (O-phenylenediamine) (PoPD) and chlorpyrifos as template molecule. Typically, TiO2 
nanotube arrays do not show photocurrent unless exposed to UV light, whereas molecularly 
imprinted PoPD/Au nanoparticle-coated TiO2 NTAs demonstrate photocurrent generation in the 
visible light range of 400-540 nm. Indeed, PoPD generates photoelectrons under visible light and 
supports HOMO to LUMO electron transitions, whereas Au NPs increase the rate of electron 
injection into the conduction band of TiO2 nanotubes, thus contributing to the overall 
photocurrents. The resulting biosensor had a fast response time (10 s) and a linear behavior in the 
0.05-10 µmol/l range, with a detection limit of 0.96 nmol/l. 
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In another study from Xin and coworkers, adsorption of dopamine on TiO2 NTAs enabled 
the achievement of highly sensitive and selective biosensors and the neurotransmitter detection in 
mouse brain [58]. Dopamine supported spatial separation of photogenerated charges, with holes 
localizing on dopamine, and electrons on TiO2 NTs. By drastically reducing charge recombination, 
the obtained biosensor demonstrated increased photocurrent and even self-cleaning behavior under 
solar light. It showed a linear response in the 0.001-25 µM dopamine range, with detection limit 
of 0.15 nM and a sensitivity of 1.343 µA/cm2 µM. The biosensor also enabled detection of 
dopamine in mouse brain while demonstrating low sensitivity to a number of catechol derivatives. 
No interference occurred from ascorbic acid, uric acid, glucose, cysteine and glutathione.  
Other interesting studies on the exploitation of the smart properties of TiO2 NTAs will not 
be discussed in detail here for the sake of conciseness, but interested readers are encouraged to 
refer to works on acethylthiocholine [63], cystatin C [60], lactate [56], and rhodamine G or glucose 
[57]. The aforementioned examples demonstrate the great potential of both plain TiO2 nanotube 
arrays and hybrid platforms based on TiO2 NTAs in detecting very different types of analytes with 
high sensitivity and selectivity, thanks to the analyte molecular imprinting and to the mediation of 
biorecognition elements. However, for these devices to be provided to the patients in the future, 
more studies on analyte detection in complex matrices are necessary, as well as investigations on 
multianalyte detection. 
 
1.6 Conclusions 
TiO2 nanotube arrays have proven to be highly versatile platforms for addressing/exploring 
biological responses in many in vitro contexts (biosensors included), and have also shown great 
potential in the fields of tissue engineering and drug delivery. To date, studies on complex 
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biological environments (such as whole organisms) are scarce yet highly desirable in order to make 
these devices available to the end point-of-care. In particular, future studies should take advantage 
of the large body of scientific evidences on the topic, and focus on the long-term stability and 
storage of these materials, as well as their long-term interaction with biological entities. Most 
importantly, further protocols for remote control of platforms based on TiO2 NTAs (alone or in 
association with other nanomaterials) should be conducted in order to fully exploit their active 
properties for tissue shaping/stimulation, controlled release of therapeutic doses of pharmaceutical 
cargoes and quantification of chemical species, either alone or in combination. This will allow for 
the development of smart multifunctional biomedical devices that can ultimately improve 
diagnostics and therapeutics. 
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TiO2-based nanotopographical cues attenuate the restenotic phenotype in 
primary human vascular endothelial and smooth muscle cells 
 
2.1 Abstract  
Coronary and peripheral stents are implants that are inserted into blocked arteries to 
restore blood flow. After stent deployment, the denudation of the endothelial cell layer and the 
resulting inflammatory cascade can lead to restenosis, the renarrowing of the vessel wall due to 
the hyperproliferation and excess matrix secretion of smooth muscle cells. Despite advances in 
drug-eluting stents (DES), restenosis remains a clinical challenge, and can require repeat 
revascularizations. In this study, we investigated how vascular cell phenotype can be modulated 
by nanotopographical cues on the stent surface, with the goal of developing an alternative 
strategy to DES for decreasing restenosis. We fabricated TiO2 nanotubes and demonstrated that 
this topography can decrease SMC surface coverage without affecting endothelialization. In 
addition, to our knowledge, this is the first study reporting that TiO2 nanotube topography 
dampens the response to inflammatory cytokine stimulation in endothelial and smooth muscle 
cells. We observed that compared to flat titanium surfaces, nanotube surfaces attenuated TNFα-
induced VCAM-1 expression in ECs by 1.8-fold, and decreased TNFα-induced SMC growth by 
42%. Further, we find that the resulting cellular phenotype is sensitive to changes in nanotube 
diameter, and that 90 nm diameter nanotubes leads to the greatest magnitude in cell response 
compared to 30 nm or 50 nm nanotubes.   
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2.2. Introduction  
Coronary stenting is a procedure for opening blocked arteries. Post-procedure, the 
renarrowing of the artery through restenosis is a persisting complication that requires 
revascularizations[1]. Restenosis is caused by injury to the vessel wall during stent deployment, 
which denudes the endothelium and triggers an inflammatory cascade due to the release of 
proinflammatory cytokines, chemokines, and the expression of adhesion molecules [2], [3]. 
Subsequently, the inflammation recruits smooth muscle cells (SMC) to migrate to the vessel 
lumen, where the cells hyperproliferate and secrete excess extracellular matrix [4], [5]. This 
leads to the formation of the restenotic lesion, which renarrows the vessel and causes the failure 
of stents to maintain patency. Restenosis can present as recurrent angina or acute myocardial 
infarction in some patients, and may require repeat revascularization.  
Drug-eluting stents (DES) inhibit the proliferation of SMCs and decrease restenosis, thus 
reducing the risk for repeat vascularizations [6], [7]. However, they also inhibit endothelial cell 
(EC) function and delay endothelial healing, leading to an increased risk of thrombosis [8]. 
Moreover, a meta-analysis of randomized clinical trials suggested that there is an increased 
mortality rate following application of paclitaxel-coated balloons and stents in patients with 
peripheral arterial disease (PAD) [9]. This study led the FDA to issue a warning letter to health 
care providers, cautioning them to weigh the relative risks and benefits of paclitaxel-coated 
stents and balloons for their patients. The risks of DES motivate the development of an 
alternative strategy to decrease restenosis in a safe and effective manner. The ideal stent surface 
would allow for rapid and functional reendothelialization and the suppression of SMC 
proliferation, in order to minimize the risks of restenosis and thrombosis [10]. 
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Nanomaterials have been widely explored as therapeutic agents for many biomedical 
applications, including drug delivery and regenerative medicine [11]–[17]. In particular, 
nanoscale topographical cues have been engineered to modulate vascular cell adhesion and 
function for cardiovascular applications [18]–[21]. Titanium, a common material used in medical 
devices and implants, can be patterned into a vertically oriented, highly ordered nanotubes 
through a simple process of electrochemical anodization [22]. Studies have shown that TiO2 
nanotube surfaces can promote bovine aortic endothelial cell adhesion and proliferation, while 
also downregulating murine vascular smooth muscle cell proliferation [23].  In an in vivo rabbit 
iliac artery model, titanium stents coated with 90 nm nanotubes led to a 17% decrease in 
restenosis rates as compared to flat titanium stents [24]. This study demonstrated proof of 
concept that TiO2 nanotube coatings can decrease restenosis in vivo, but the mechanism through 
which TiO2 nanotubes decreases restenosis is not yet fully understood.  
Therefore, we sought to investigate the effect of nanotube topography on primary human 
vascular cell phenotype on a cellular level, to explain the tissue-level responses observed in vivo. 
We cultured primary human coronary artery ECs and SMCs, and quantified their relative 
coverage on the surface as well as responses to inflammation. To our knowledge, this is the first 
study that quantifies the effect of TiO2 nanotube topography on the inflammatory responses in 
primary human vascular cells. We also investigated the cell-interface interactions by quantifying 
focal adhesion kinase expression and phosphorylation. Lastly, we compared EC and SMC 
response to varying nanotube diameters, to determine whether cellular responses were dependent 
on the size and spacing of the surface features. The information revealed in this study can guide 
the design of new stent surfaces to decrease restenosis.  
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2.3 Materials and Methods 
2.3.1 TiO2 Nanotube Anodization   
Titanium foil sheets (0.127 mm thickness, 99.7% trace metals basis), aluminum fluoride 
(Ammonium fluoride, =99.99% trace metals basis), glycerol (ACS reagent, >=99.5%), and 
ethylene glycol (ReagentPlus) were purchased from Sigma-Aldrich (Milwaukee, WI). Titanium 
foil sheets were cut into 2 cm by 2 cm squares and cleaned by sonication in a sequential bath of 
Figure 2.1 Voltage and electrolyte composition were adjusted to determine the optimal 
anodization parameters to achieve the target nanotube dimensions of 30, 50, and 90 nm.  
(A) Anodization voltage was kept constant at 15V, while the water content in the electrolyte 
was adjusted between 2.5 wt% to 15 wt%. The electrolyte contained 3 g/L ammonium 
fluoride, and between 97.5 wt% and 85 wt% ethylene glycol, adjusting for the changes in 
water content. (B) Anodization voltage was tuned from 5 V to 15 V. The electrolyte 
composition remained constant, containing 3 g/L ammonium fluoride, 10 wt% distilled 
water, and 90wt% ethylene glycol. Nanotube diameter increases as voltage increases. (C) 
Voltage was tuned between 10 V and 30 V for anodizing TiO2 foil in a glycerol electrolyte 
solution. The electrolytes contained 1.4 wt% ammonium fluoride, the indicated wt% of 
water, and the remaining wt% as glycerol. 
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Micro-90 solution (International Products Corporation), 100% acetone, and 70% ethanol. To 
fabricate titanium nanotubes, the titanium foil and an equal-sized piece of platinum foil were 
secured in a custom-made, 3D-printed holder (Figure 2.1A). The titanium and platinum foils 
were maintained parallel to each other and 19 mm apart. The foils were connected to electrodes 
using platinum wire, where the titanium foil served as the anode and the platinum as the cathode. 
The foils in the holder were submerged in an electrolyte solution, containing 90 wt% ethylene 
glycol, 9.1 wt% DI water, and 0.9 wt% ammonium fluoride. An anodic voltage of 30 V was 
applied for 60 minutes in order to fabricate the titanium nanotube coating. The nanotube surfaces 
were then annealed in a furnace at 450 ̊C for 2 hours and stored in a vacuum chamber until use.  
For fabricating 30 nm and 50 nm nanotubes (NT30 and NT50), the electrolyte solution 
was composed of 94.3 wt% glycerol, 4.3 wt% water, and 1.4 wt% ammonium fluoride. Figure 
2.2 shows the optimization of anodization parameters for achieving the target nanotube 
diameters. A 10 V or 15 V voltage was applied for 120 min for the NT30 and NT90 surfaces, 
respectively. To fabricate NT90* nanotubes, the electrolyte solution was composed of 90.6 wt% 
glycerol, 8 wt% water, 1.4 wt% ammonium fluoride. A voltage of 30V was applied for 120 
minutes. Following anodization, the foils were rinsed in DI water, then sonicated briefly in 70% 
ethanol to clean off the residual electrolyte solution. The foils were then annealed in a furnace at 
350 ̊C for 1 h.  
2.3.2 Helium Ion Microscopy  
Anodized nanotube surfaces were imaged using a Zeiss Helium Ion Microscope (HIM) at 
the University of California Berkeley Biomolecular Nanotechnology Center (Berkeley, 
California). Foils were sputter coated with gold-palladium at 10 mA for 45 s prior to imaging.  
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Cells cultured for 2 days on 90 nm-diameter nanotubes (NT90) and flat foils were fixed 
in glutaraldehyde SEM fixation buffer overnight (2.7% (v/v) glutaraldehyde, 0.1 M sodium 
cacodylate buffer), then washed 3x with 0.1M sodium cacodylate for 10 minutes each. The 
sample was then dehydrated in serial baths of 35%, 50%, 70%, 85%, 90%, 95%, and 100% 
ethanol, for at least 10 minutes each. The foils were then dried using a critical point dryer in 
100% ethanol. The cells were sputter coated with the same settings as above, and then imaged 
using HIM.  
2.3.3 Atomic Force Microscopy  
AFM was performed using a NanoWizard Ultra Speed A AFM in soft tapping mode, 
using a BudgetSensors All-In-One probe (BudgetSensors, Sofia, Bulgaria). Scans were 
performed in three different fields of view, and root mean squared roughness values were 
calculated using the Gwyddion software (Czech Metrology Institute, Jihlava, Czechia).   
2.3.4 Cell Culture and Cell Proliferation Assays  
Primary human coronary artery endothelial cells (EC) and primary human coronary 
artery smooth muscle cells (SMC) were purchased from PromoCell (Heidelberg, Germany). 
SMCs were maintained in smooth muscle growth medium-2 (SMGM-2) (PromoCell), and ECs 
were maintained in endothelial cell growth medium-2 (EGM-2) (PromoCell). ECs used for cell 
area measurements were cultured in endothelial cell growth medium-2 MV (EGM-2 MV). 
Cells were seeded onto NT90 or flat surfaces to measure the effect of surface topography 
on cell behavior. To measure cell proliferation, ECs were seeded on foils at 8,000 cells/cm2 and 
cultured for 1, 2, or 3 days. SMCs were seeded on foils at 10,000 cells/cm2 and cultured for 1, 3, 
or 5 days. Cell numbers were quantified using a CyQUANT proliferation assay (Molecular 
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Probes, USA), using DNA content as a measurement of cell number. Experiments were 
performed in triplicate.  
2.3.5 Cell staining and immunofluorescence  
 Cells were then fixed with 4% paraformaldehyde for 10 minutes at room temperature, 
washed three times with PBS for 5 minutes each, then permeabilized with 0.1% Triton X-100 for 
5 minutes.  
For immunofluorescence, fixed and permeabilized samples were blocked for 1 hour at 
room temperature with 10% goat serum, then incubated with primary antibody overnight at 4 ̊C.  
Either anti-paxillin [ab32084] (Abcam, Burlingame, CA) or anti-vinculin [V9131] (Thermo-
Fisher, Waltham, MA) antibodies was used to visualize focal adhesions. The antibodies were 
used at 1:250 and 1:400 dilutions, respectively. Cells were then washed and incubated with 
secondary antibodies for 30 minutes at room temperature. Lastly, cells were counterstained with 
Alexa Fluor 488-tagged phalloidin (Invitrogen, Carlsbad, CA) at a 1:500 dilution, and with DAPI 
at a 1:1000 dilution. Microscopy images were acquired using a Nikon 6D optical microscope 
(NIKON Instruments, Inc., Melville, NY) with 4–20x magnification. All image quantification 
was performed using ImageJ.  
2.3.6 Cell Area Measurements  
To measure cell area, EC and SMC were cultured for 24 h on NT90 or flat surfaces. The 
cells were fixed, permeabilized, and stained with phalloidin and DAPI as described previously.  
Cell area quantification was performed using ImageJ. The images were thresholded, individual 
cells were selected, and their areas was measured. Measurements were taken from at three foils 
per condition, with at least three fields of view measured per foil.  
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2.3.7 Quantitative Real-Time PCR  
To measure gene expression, the cells were cultured on NT90 or flat surfaces for 24 h. 
For ECs, the cells were then stimulated with 2 ng/mL of human TNFα (R&D Systems, 
Minneapolis, MN) for 4 h. mRNA was extracted using the RNEasy Mini Kit (Qiagen). Reverse 
transcription was performed using the iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories, 
Hercules, CA). qPCR was performed using Fast SYBR Green Mastermix (Life Technologies, 
Grand Island, NY) and a Viia7 qPCR machine (Life Technologies, Carlsbad, CA). The relative 
transcript quantities were calculated using the ΔΔCt method and normalized to the housekeeping 
gene encoding RPL19.  Custom-made DNA primers were purchased from Integrated DNA 
Technologies (Coralville, IA) and the sequences are shown in Table 2.1.   
 
Table 2.1 Primer sequences used for qPCR 
 
Gene Primer Sequence  
RPL-19 Fwd: TCGCCTCTAGTGTCCTCCG 
Rev: GCGGGCCAAGGTGTTTTTC 
VCAM-1 Fwd: GGGAAGATGGTCGTGATCCTT 
Rev: TCTGGGGTGGTCTCGATTTTA 
CCL-2 Fwd: CAGCCAGATGCAATCAATGCC 
Rev: TGGAATCCTGAACCCACTTCT 
 
2.3.8 ELISA  
Collagen production was measured using the Human Pro-Collagen I alpha 1 ELISA Kit 
(Abcam, Cambridge, UK). SMCs were cultured on NT90 or flat surfaces for 24 h. The 
conditioned media was collected to measure secreted pro-collagen I concentration, and the cell 
extract was collected to measure pro-collagen I concentration within the cells. Cell extracts were 
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prepared using the extraction buffer and enhancer provided in the kit, following manufacturer 
instructions.  
To measure MCP-1 secretion, SMCs were cultured on NT90 or flat surfaces for 24 h. 
Cells were treated with either 1 ng/mL of TNFα, or an equal volume of PBS as a vehicle control. 
All cells were incubated for an additional 24 hours. The conditioned media was then removed 
and MCP-1 concentration was measured using a Human CCL2/MCP-1 Quantikine ELISA Kit 
(R&D Systems) according to manufacturer instructions.  
To measure FAK and pFAK expression, SMCs or ECs were cultured on TiO2 nanotube 
and flat surfaces for 24 hours. The foils were washed with PBS, and cells were lysed with Cell 
Extraction Buffer (Invitrogen, Waltham, MA, USA) supplemented with Pierce Protease and 
Phosphatase Inhibitor Mini Tablets (Thermo Scientific, Waltham, MA, USA) for 10 minutes on 
ice. Cells were then scraped off the surface, transferred to centrifuge tubes, and spun down at 
10,000 RPM for 10 minutes at 4 ̊C. The supernatant was removed and cell lysates were analyzed 
using the FAK (Total) Human ELISA Kit and FAK (Phospho) [pY397] Human ELISA Kit 
(Invitrogen, Waltham, MA, USA). Total FAK concentration was normalized to total protein 
concentration of the same sample, as measured using a BCA assay. pFAK concentration was 
normalized to total FAK concentration of the same sample. Experiments were performed in 
triplicate or quadruplicate.  
2.3.7 Statistical Analysis  
Experiments were performed in triplicate or quadruplicate, and are reported as mean ± 
standard deviation (SD). Statistical analysis was performed using GraphPad Prism 6. Student’s t-
tests were used to compare cell responses on flat versus NT90 surfaces. For the cell number 
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assays over 3 time points, a multiple t-test was performed using the Holm-Sidak method for 
multiple comparisons correction.  
For experiments comparing flat, NT30, NT50, and NT90 surfaces, One-Way ANOVA 
was performed followed by Tukey’s method for multiple comparisons correction. For the cell 
number assays comparing cell numbers on these surfaces, a Two-Way ANOVA was performed, 
followed by Tukey’s method for multiple comparisons correction. 
 
2.4. Results   
2.4.1 Nanotube surface characterization and cell morphology  
Figure 2.2 (A) A schematic of the electrochemical anodization of TiO2 nanotube coatings on 
titanium foil using a custom 3D printed holder. Helium ion microscopy (HIM) images of (B) flat 
and (C) NT90 surfaces. Atomic Force Microscopy (AFM) projections of (D) flat and (E) NT90 
surfaces. D=Diameter; RMS=Root-mean-squared roughness. Scale bar = 200 nm. 
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Helium ion microscopy images revealed that TiO2 nanotube surfaces with 90 nm 
diameters (NT90) were successfully fabricated (Figure 2.1). The average nanotube diameter 
(Figure 2.1C) and root-mean-squared roughness (RMS) (Figure 2.1E) are reported.  
Ridges can be observed on flat surfaces, likely due to draw marks formed during the 
process of casting the titanium sheets. AFM revealed that NT90 surfaces have greater roughness 
than the flat surfaces, with an RMS value of 55 nm as compared to 18 nm for flat (Figure 2.1). 
EC and SMC both adhere to the surfaces and can form cytoplasmic projections including 
filopodia on both the flat and NT90 surfaces (Figure 2.3). 
  
Figure 2.3 Representative HIM images of primary human coronary endothelial muscle cells on 
(A) flat (scale bar = 2 μm) and (B) NT90 surfaces (scale bar = 200 nm). Representative HIM 
images of primary human coronary smooth muscle cells on (C) flat (scale bar = 1 μm) and (D) 
NT90 surface (scale bar = 2 μm). Cells were fixed after 2 days of culture. Filopodia are 
indicated by white arrows. 
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2.4.2 NT surface decreases SMC cell coverage without affecting EC coverage 
The cell number and cell area of ECs cultured on flat and NT90 surfaces were measured 
over the course of 3 days (Figure 2.4A, B). For both NT90 and flat surfaces, cell growth was 
negligible between days 1 and 2, before increasing after day 2. This delay may be due to the time 
Figure 2.4 EC and SMC cell coverage on flat and NT surfaces. (A) EC and (E) SMC cell 
numbers on flat and NT surfaces were measured using a CyQUANT assay, which 
quantifies DNA content in cell lysates. (B) EC and (F) SMC area were quantified using 
fluorescence microscopy and ImageJ. Representative images of (C, D) ECs and (G, H) 
SMCs stained with phalloidin (green) and DAPI (blue) cultured on flat and NT surfaces are 
shown. Scale bar: 150 μm. 
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needed for sufficient serum protein to adsorb onto the surface and allow for cell attachment and 
spreading. For ECs, the number of cells is about 1.5-fold greater on NT90 than flat surfaces after  
1 day. By day 3, cell numbers were more similar between the two surfaces (Figure 2.4A). When 
we quantified EC spreading on NT90 surfaces, we found that the cell area decreased by about 
40% on NT90 surfaces. We then quantified overall cell coverage by calculating the percent of 
the foil surface covered by EC cellular material to gauge the effect of nanotubes on 
endothelialization (Figure 2.5). We found that when accounting for both cell number and cell 
area, the overall cell coverage on flat and NT90 surfaces are similar over the course of 7 days 
(Figure 2.5.) Further, in confluent endothelial cell layers, we observed staining for 
circumferential actin bundles along cell-cell junctions on both flat and NT90 surfaces (Figure 
2.8B, D, F, H). The accumulation of polymerized actin at cell-cell contacts have been shown to 
contribute to VE-cadherin stabilization [25]. Therefore, our results suggest that intact endothelial 
layers can be formed on both flat and NT90 surfaces.  In summary, NT90 surfaces increases the 
number of ECs compared to flat surfaces, but decreases the average cell area, leading to a similar 
extent of endothelialization as compared to flat titanium. 
The number of adherent SMCs on day 1 is similar on both flat and NT90 surfaces (Figure 
2.4B). After 3 days, the is a trend of fewer SMCs on NT90 than flat surfaces. By day 5, there are 
40% fewer SMCs on NT90 than flat surfaces (p<0.05). In addition to the differences in cell 
number, we observed that SMCs are also approximately 40% smaller surface areas on NT90 as 
compared to flat surfaces (Figure 2.4C, D). This suggests that the cells are less spread on NT90 
as compared to flat surfaces. For SMCs, the decrease in both cell number and cell area of SMCs 
on NT90 surfaces leads to a substantial decrease in overall SMC coverage (Figure 2.4G, H). In 
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summary, we observe that NT90 surfaces can decrease SMC coverage without adversely 
affecting endothelialization.  
 
 
  
Figure 2.5 ECs were cultured on (A-D) flat and (E-H) NT90 surfaces for 1, 3, 5 or 7 days. At the 
end of each time point, the cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% 
Triton X-100, and stained with phalloidin (green) and DAPI (blue). Cells were imaged 
fluorescence microscopy. Cell coverage shown in (I) was quantified cell coverage by 
thresholding the images in ImageJ and measuring the percentage of the field of view covered by 
endothelial cells. Scale bar: 200 μm. 
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2.4.3 NT surfaces decrease the inflammatory responses in endothelial and smooth muscle 
cells.  
Several cytokines are implicated in the 
development of restenosis, including MCP-1 
[26], IL-6  [26], [27] and TNFα [28]. We chose 
TNFα as a model cytokine to simulate an 
inflammatory environment in our in vitro 
cultures. We assessed how vascular ECs and 
SMCs cultured on flat and NT90 surfaces 
responded to TNFα stimulation.  
To probe the effect of NT90 surfaces on 
the inflammatory response in ECs, we 
measured the gene expression of VCAM-1, 
which encodes an adhesion molecule that 
mediates immune cell binding and tissue 
inflammation [29], [30]. Increased levels of 
VCAM-1 expression is correlated with patients 
who develop restenosis [31], [32]. We used 
qPCR to measure the expression of VCAM-1 in 
ECs cultured on NT90 and flat surfaces, and 
found that NT90 decreased VCAM-1 expression 
by 1.8-fold (Figure 2.6A). This result suggests 
that NT90 has a protective effect against the 
stimulation of the inflammatory molecule TNFα 
Figure 2.6 The effect of nanotube topography 
on inflammatory response. (A) VCAM-1 
gene expression in ECs. (B) SMC cell 
numbers when cultured on flat or NT90 
surfaces in control media or under stimulation 
with 2 ng/mL TNFα, an inflammatory 
cytokine and known mitogen for SMCs. (C) 
MCP-1 secretion by SMCs cultured on flat or 
NT surfaces was measured in conditioned 
media using ELISA. Data are expressed as 
mean ± SD 
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on ECs. The decreased expression of adhesion molecules may dampen the inflammatory cascade 
and attenuate overall tissue inflammation in the area of stent deployment.  
NT90 has a similar anti-inflammatory effect in SMCs stimulated with TNFα. This effect 
was seen in two ways: inflammation-induced cell growth and cytokine production. Firstly, 
during the pathogenesis of restenosis, inflammatory cytokines induce the hyperproliferation of 
SMCs. TNFα is one of the mitogens that stimulates SMC proliferation [33], [34]. As expected, 
we observed that TNFα increases cell number on both flat and NT90 surfaces after 48 hours, as 
compared to control media that does not contain TNFα. When cultured on flat surfaces, SMC 
Figure 2.7 (A) SMCs cultured on NT surfaces increases the gene expression of CCL-2, which 
encodes the protein MCP-1. (B) Secretion of MCP-1 from SMCs cultured on flat or NT surfaces, 
in the presence of inflammatory cytokine stimulation (1 ng/mL TNFα). Pro-collagen I content of 
SMCs cultured on flat or NT90 surfaces was quantified using ELISA. Pro-collagen I 
concentration in (C) conditioned media, (D) cell extract. Data are expressed as mean ± SD. 
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numbers increased by 42% when stimulated with TNFα (Figure 2.6B). However, when cultured 
on NT90, SMC numbers increased by only 34%. In the presence of TNFα, there were 29% fewer 
SMCs on NT90 than those cultured on flat surfaces. These data indicate that NT90 may be 
protective against the mitogenic effects of TNFα. Secondly, SMCs also respond to inflammation 
by producing their own cytokines, including MCP-1. We observed that the gene expression of 
CCL-2, the gene that encodes MCP-1, increased when SMCs were cultured on NT90 (Figure 
2.7A). However, we found the opposite trend in protein secretion, which is likely due to the 
decrease in total cell number. Under standard media conditions, we observed that SMC cultured 
on NT90 secreted 39% less MCP-1 than those cultured on flat surfaces (Figure 2.6C). When 
stimulated with 1 ng/mL TNFα, SMCs secrete 18% less MCP-1 when cultured on NT90 
(p=0.055) (Figure 2.7B). These results indicate that nanotube surfaces can dampen the 
pathogenesis of restenosis by decreasing the inflammatory response of SMCs.  
2.4.4 Focal Adhesion Kinase (FAK) expression and phosphorylation 
Changes in focal adhesion kinase activity likely mediates other downstream signaling 
processes. Focal adhesions and the actin cytoskeleton in ECs cultured on flat and NT90 surfaces 
can be seen in Figure 2.8. We observe via vinculin staining that punctate focal adhesions can be 
formed on both flat and NT90 surfaces. We quantified FAK expression and phosphorylation via 
ELISA, and found that ECs cultured on NT90 had a similar level of total FAK and pFAK protein 
levels as compared to flat surfaces (Figure 2.9A, B). This result suggests that FAK total 
expression and phosphorylation is not a mechanism that mediates the differences that we observe 
in EC behavior on NT90 surfaces.  
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Figure 2.8 (A-H) ECs were cultured on on (A-D) flat or (E-H) NT90 surfaces for 1 day, and then 
the cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, and 
stained with (A, E) DAPI (blue), (B,F) phalloidin (green), (C, G) anti-vinculin (red). Merged 
images are shown in (D, H). (I-P) HCASMCs were cultured on (I-L) flat or (M-P) NT90 surfaces 
for 1 day, then fixed and permeabilized as described for HCAECs. SMCs were then stained with 
(I, M) DAPI (blue), (J,N) phalloidin (green), (K, O) anti-paxillin (red).  Merged images are 
shown in (L, P). (A-H) scale bar: 25 μm. (I-P) scale bar: 50 μm. 
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SMCs cultured on both flat and NT90 surfaces were able to form punctate focal 
adhesions, as shown in Figure 2.8 with paxillin staining. We also observed a 5-fold decrease in 
total FAK expression, as quantified by ELISA, when the cells are cultured on NT90 (p<0.001) 
(Figure 2.9C). This was as expected because nanotube surfaces have decreased available 
adhesive area compared to flat surfaces. Interestingly, there was an increase in the ratio of 
phosphorylated FAK on SMCs cultured on NT90 compared to those cultured on flat surfaces 
(Figure 2.9D). This could be a mechanism for the cells to compensate for traction forces lost due 
to the decrease in total FAK expression.  
  
Figure 2.9 Total FAK and pFAK were quantified by ELISA using cell lysates from (A), (B) 
ECs and (C), (D) SMCs cultured on flat and NT90 surfaces. Total FAK concentration was 
normalized to total protein content. pFAK concentration was normalized to total FAK 
concentration. Data are expressed as mean ± SD. 
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2.4.5 Nanotube effects on EC and SMC response is diameter-dependent  
We fabricated TiO2 nanotubes with 30 nm and 50 nm diameters to investigate whether 
tuning TiO2 nanotube diameter has an effect on cell responses. To fabricate these smaller 
diameters, the electrolyte base was switched from ethylene glycol to glycerol, a more viscous 
liquid that changes the kinetics of the anodization process to result in different nanotube features. 
Anodization parameters including electrolyte content and voltage were tuned to achieve these 
specified diameters, and the optimization of the parameters are shown in Figure 2.2. These 
surfaces were characterized using HIM and AFM as indicated above and representative images 
are shown (Figure 2.10).  
Figure 2.10 Fabrication and characterization of (A, C) NT30 and (B, D) NT50 surfaces. (A, 
B) HIM images and (C, D) AFM 3D-projections are shown. D = diameter; RMS = root-
mean-squared roughness. Scale bar = 200 nm. 
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The number of ECs on all NT surfaces, regardless of diameter, was increased as 
compared to flat surfaces on day 1 (Figure 2.11A). All nanotube surfaces increased EC cell 
numbers over 3 days. For SMC, all nanotube surfaces decreased SMC cell numbers compared to 
flat, but only NT90 led to a statistically significant decrease in cell number by day 5 (Figure 
2.11C).  
Next, we measured how response to inflammation changes with nanotube diameter. All 
NT surfaces led to a decrease in VCAM-1 expression in ECs cultured with 2 ng/mL of TNFα 
(Figure 2.11B). There was a trend of greater reduction in VCAM-1 expression correlating to the 
larger NT diameters, with NT90 leading to the greatest reduction in adhesion molecule gene 
expression. 
For SMCs under standard media conditions, all NT surfaces led to slight reductions in 
cell number as compared to flat, with the greatest magnitude of cell number reduction on NT90 
(Figure 2.11D). These results agree with cell number results in Figure 2.6C. In the presence of 2 
ng/mL TNFα, all NT surfaces led to decreased cell numbers as compared to flat surfaces.  
When measuring SMC MCP-1 secretion, we observed that NT30 and NT50 led to similar 
levels of MCP-1 secretion as flat surfaces, and only NT90 led to a statistically significant 
decrease (p<0.01) as compared to all other NT or flat surfaces (Figure 2.11E). These data 
demonstrate that NT90 led to the greatest reduction in anti-inflammation markers for both ECs 
and SMCs compared to flat and NT surfaces with smaller diameters.  
We noted that nanotube surfaces with smaller diameters, also had decreased overall 
surface roughness, possibly because the different electrolytes and voltages used led to varying 
growth rates of the nanotubes on the surface. NT90 surfaces have an RMS of 58 nm, whereas 
NT30 and NT50 have a root-mean-squared roughness (RMS) of 24 nm and 29 nm respectively 
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(Figures 1, 6) Therefore, we set out to change the roughness independently from the diameter to 
investigate whether roughness or diameter is the primary driving force behind these observed 
changes in cellular response. We fabricated NT90*, a nanotube surface with 90 nm diameter  
Figure 2.11 The effect of varying NT diameter on EC and SMC response. Cell growth rates on 
flat and NT surfaces using (A) ECs and (D) SMCs. Significance values are represented as 
follows: x NT30; # NT50; *NT90. One symbol: p<0.05; two symbols: p<0.01. (B) VCAM-1 
mRNA expression in ECs cultured on flat and NT surfaces. Values are normalized to mRNA 
expression on flat surfaces. (D) SMC cell numbers cultured on flat and NT surfaces, in control 
media and in media containing 2 ng/mL TNFα. (E) MCP-1 secretion by SMCs cultured on flat 
and NT surfaces. Note: Data shown here for flat and NT90 surfaces are identical as those in 
previous figures. They are shown here as a reference for comparison purposes. 
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Figure 2.12 The effect of varying TiO2 nanotube surface roughness EC and SMC phenotype. 
NT90* surfaces were characterized using (A) helium ion microscopy and (B) AFM. (C) EC 
surface coverage was measured using CyQUANT over 3 days. (D) SMC cell number on day 1 
was quantified by fluorescence microscopy and ImageJ. (E) EC and (F) SMC cell area were 
quantified by fluorescence microscopy and ImageJ. (G) EC VCAM-1 expression after 2 ng/mL 
TNFα stimulation was measured by qPCR. (H) SMC numbers after stimulation with 2 ng/mL 
TNFα was measured by CYQUANT. 
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nanotubes (Figure 2.12A), but 33 nm RMS roughness (Figure 2.12B), which was more similar to 
the roughness of NT30 and NT50 surfaces. We observed that SMC cultured on NT90* surfaces 
had similar cell adhesion and cell area to those cultured on NT90 surfaces (Figure 2.12D, S5F). 
ECs cultured on NT90* surfaces had similar cell numbers as compared to those cultured on 
NT90 (Figure 2.12C), but cell area on NT90* was increased relative to NT90, and more closely 
resembled cell areas of ECs cultured on flat surfaces (Figure 2.12E). This suggests while 
roughness did not change SMC response, EC response were affected by changes in surface 
roughness. When we then assayed the effect of NT90* on inflammatory responses in terms of 
EC VCAM-1 expression and cytokine-induced SMC growth, we found no differences compared 
to flat surfaces (Figure 2.12G, H). Therefore, while a decrease in roughness in the NT90* 
surfaces may potentially improve EC surface coverage, the anti-inflammatory effects were 
diminished. 
 
2.5. Discussion 
Tuning cell behavior on the stent surface using nanotube topography has several 
advantages: 1) The anodization process for patterning surfaces is simple and compatible with 
metallic substrates, 2) the surface topography can be modified without altering the bulk 
mechanical properties of the stent, and 3) it avoids the use of the toxic drugs commonly used in 
DES. In this study, we investigated how TiO2 nanotube topography can affect the responses of 
vascular endothelial and smooth muscle cells, with respect to their roles in restenosis. We 
quantified three major hallmarks of restenosis: EC coverage, SMC coverage, and inflammatory 
responses.  
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2.5.1 TiO2 nanotube decrease SMC coverage without changing endothelialization 
When SMCs were cultured on NT surfaces, we found that cell numbers were 40% less on 
NT90 by day 5. We also found that cell area was 40% smaller on NT90. This results in an 
overall decrease in cell coverage when SMCs were cultured on nanotube surfaces. This result 
agrees with previous literature reporting that NT surfaces decrease cell mouse aortic vascular 
smooth muscle cells (MOVAS) proliferation [23] and decrease SMC coverage [35]. A decrease 
in SMC coverage on the stent surface could lead to a decrease in restenosis in vivo.  
For endothelial cells, we found that NT surfaces resulted in a similar rate and extent of 
endothelialization compared to flat surfaces (Figure 2.5). While the cell number increased, cell 
area decreased (Figure 2.4). Previous work has also shown that NT surfaces increase HUVEC 
cell number as compared to flat [35], which agrees with our results shown here. However, the 
study also shows that HUVEC cell spreading is not affected by NT surfaces, thus leading to an 
increase in total cell coverage attributed to the increase in cell number. The difference in our 
results may be due to different cell types used, or due to distinctions in the fabrication of NT 
surfaces. In our study, we found that the endothelialization was comparable on both NT90 and 
flat surfaces for primary human coronary artery endothelial cells. 
Since the restenotic lesion is composed of both cellular material and secreted matrix 
proteins, we also measured pro-collagen I secretion from SMCs.  Collagen I is one of the major 
components of the restenotic lesion [36], and pro-collagen I is the un-crosslinked precursor to the 
crosslinked, insoluble collagen I.  As shown in Figure 2.7C and 2.7D, SMCs cultured on flat and 
NT90 surfaces have similar pro-collagen I content per cell, as measured both internally in the 
cell lysate, and externally in the conditioned media. This suggests that tissue-level changes in 
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collagen I content would likely be driven by total cell number, and not the level of production 
per cell.  
2.5.2 Response to inflammation  
Inflammation plays a significant role in the development of restenosis [27], [37], [38]. 
Therefore, we set out to assess how NT surfaces affect the responses of ECs and SMCs to the 
inflammatory cytokine TNFα, which is implicated in restenosis [28].  
Our data demonstrates that NT topography decreases the gene expression of VCAM-1 by 
1.8-fold. VCAM-1 encodes adhesion molecules that contribute to the inflammation within the 
vessel wall. Their expression is induced by inflammation, and in turn, they increase endothelial 
cell activation and mediate immune cell binding and extravasation [29], [30]. In particular, the 
implication of VCAM-1 in restenosis has been previously reported, and its blockade can lead to 
decreased restenosis. For example, blocking VCAM-1 using monoclonal antibodies was 
demonstrated to reduce neointimal formation after periadventitial carotid artery injury in 
genetically hypercholesterolemic mice [39]. In addition, siRNA inhibition of VCAM-1 reduced 
neointimal formation after surgical mechanical injury of the carotid artery in a rat model [40]. 
Taken together, the decrease in VCAM-1 expression is likely a mechanism through which NT 
topography can decrease tissue-level inflammation and attenuate restenosis.  
We also found that when SMCs are cultured on NT90, TNFα induced a smaller degree of 
hyperproliferation as compared to SMCs cultured on flat surfaces.  This indicates that in an 
inflammatory environment, there is a significant decrease in SMC number when cells are 
cultured on NT90 surfaces.  NT90 surfaces may act in concert with TNFα receptor signaling to 
attenuate SMC coverage on the surface, since cell numbers on the two surface types are not 
statistically significantly different without the presence of TNFα. 
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 NT90 also affects SMC response to inflammation by decreasing levels of MCP-1 
produced. MCP-1 mediates monocyte recruitment and activation, which is a necessary 
contributor to restenosis [41]. MCP-1 is produced by many cell types, including macrophages, 
endothelial cells, fibroblasts, and smooth muscle cells. MCP-1 production is induced by other 
growth factors and cytokines, causing the cell to amplify the inflammatory cascade. We found 
that under both normal and inflammatory conditions, the total amount of secreted MCP-1 is 
lower on NT90 surfaces as compared to flat. This difference is likely due to the decreased 
numbers of SMC on NT surfaces contributes to the decrease in total MCP-1 concentration.  
Our study indicates that TiO2 nanotubes can curb the inflammatory cascade surrounding 
restenosis in several ways: 1) decreasing EC expression of adhesion molecules, 2) decreasing 
SMC mitogenesis in response to inflammatory cytokines like TNFα, and 3) decreasing the 
production of inflammatory cytokines such as MCP-1 by SMC.  
2.5.3 The effect of NT surfaces on focal adhesion expression and phosphorylation  
Cells sense mechanical signals via integrins, which physically engage the ECM and can 
become the nucleation points for focal contacts, and subsequently focal adhesions. Integrins also 
trigger intracellular signals that regulate remodeling of the actin cytoskeleton and other 
downstream activities. Focal adhesion kinase (FAK), as well as Src, paxillin, and several other 
adaptor proteins are associated with integrins on the membrane [42], and affect many 
physiological responses including proliferation, migration, and growth factor signaling.  
We investigated how NT surfaces affect FAK expression and phosphorylation. For 
endothelial cells, we found that NT90 surfaces does not cause significant difference in FAK 
expression or levels of phosphorylation. However, because ECs do demonstrate different 
behavior on NT90 surfaces, as evidenced by smaller surface area, differences in cell numbers, 
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and decreased VCAM-1 expression, we believe that the nanotube topography is regulating cell 
phenotype in a different mechanism. Some potential examples include the regulation of focal 
adhesion localization, composition of the plaque components, and focal adhesion size [43].  
In smooth muscle cells, nanotube topography led decreased total FAK expression, but an 
increased ratio of phosphorylated FAK. Increased FAK expression is correlated with increased 
traction forces and cell spreading area [44], [45], which agrees with our data illustrating that cells 
on flat surfaces, which had higher FAK expression, also had greater spreading area compared to 
NT90 surfaces.  The decreased FAK expression could be explained by the decreased amount of 
available surface area on TiO2 nanotube surface, since cells can likely only adhere to the walls of 
the tubes and not the void space in the middle of the nanotube. This means that there is less area 
for cells to attach and form focal adhesions. Despite the decrease in FAK protein expression, 
there is an increase in the ratio of phosphorylated FAK. This could be a compensatory 
mechanism through which the cells try to exert enough traction force despite the decreased 
number of focal adhesions. Further, there is a well-documented cross-talk between growth factor 
receptor and integrin-mediated signaling in cells [46], [47]. The formation and phosphorylation 
of FAK is likely to affect growth-factor signaling and other downstream cellular processes, 
which likely contributes to the differences we observed in SMC response to TNFα stimulation 
when cultured on NT90 versus flat surfaces.  
2.5.4 Vascular cell responses to TiO2 nanotubes are diameter-dependent  
Cellular response to topography can be influenced by the size and density, and regularity 
of the features [48], [49] , and the response is often cell-type dependent [50]. Cells attach to 
substrates via integrins, and several studies have shown that ECM ligand and integrin spacing 
affect focal adhesion formation, growth factor signaling, proliferation, and more [43], [48], [51]. 
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The geometric constraints of the TiO2 nanotube surfaces affect the possible patterns of integrin 
clustering, focal adhesion activation, and subsequent downstream signaling events. Further, TiO2 
nanotubes with varying diameters have been shown to exert different effects on cells. However, 
conflicting reports exist regarding the diameters that are optimal for eliciting the desired cellular 
response for a stent material. For example, Park et al found that TiO2 nanotubes of 15-30 nm in 
diameter can increase endothelial cell adhesion, whereas nanotubes of 100 nm in diameter 
caused increased apoptosis [20]. On the other hand, Zhong et al reported that TiO2 nanotubes of 
110 nm increased endothelial cell proliferation [35]. We tuned nanotube diameter to study how it 
affects cell-substrate interactions and changes in cell growth and inflammation.   
In terms of endothelial cell number, we found that there is no statistically significant 
difference in cell number amongst any of the TiO2 nanotube surfaces. This data suggests that 
while the presence of nanotubes has an effect on cell number, changing the nanotube size does 
not significantly affect EC cell adhesion and growth. For SMC cells, the largest nanotubes, NT90 
resulted in the greatest decrease in SMC cell number compared to flat and smaller-diameter 
nanotube surfaces. Our findings with endothelial cells are agree with previous studies on the 
effect of RGD ligand density on cell adhesion and cell area. Le Saux et al fabricated surfaces 
with controlled RGD ligand density and size, and measured endothelial cell adhesion and cell 
area[48]. The study reported that with decreased RGD density, cell adhesion increased 
significantly until a certain threshold, and then began to decrease. In our study, nanotube 
surfaces can be comparable to surfaces with decreased ligand density, since the nanotube 
geometry constrains the available adhesive area for cells to attach. We found that nanotube 
surfaces affect cell spreading area in both cell types, but the effect was cell type-dependent.  
Whereas nanotubes increased EC number, they decreased SMC number. This differential 
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response observed once again illustrates that the response to changing feature sizes depends on 
the cell type, and we can take advantage of this differential cell response to engineer material 
surfaces to have specific therapeutic outcomes.   
We measured functional outputs in response to TiO2 nanotubes of varying diameters. In 
some cases, the presence of nanotubes of any diameter led to significant changes in cell 
behavior. For instance, SMC growth in response to TNFα stimulation was significantly 
decreased on all nanotube surfaces compared to flat titanium. In other cases, the response to 
diameter is a graded response. For example, increasing nanotube diameters led to greater 
decreases in VCAM-1 expression in ECs. Lastly, there are other cases in which only the largest 
NT90 surfaces had an effect on cell phenotype, while NT30 and NT50 cause no change 
compared to flat surfaces. This was the case of MCP-1 production in SMCs. Given these 
observations, it is possible that there also exists a threshold of ligand spacing and density that is 
necessary to elicit a specific response, and that this difference is dependent on the cell type and 
the signaling pathways involved. 
We also found that changing surface roughness independently of nanotube diameter led 
to changes in EC surface area, but not affect SMC area and cell number. Moreover, while NT90* 
surfaces with decreased surface roughness could potentially increase EC coverage, the anti-
inflammation effects were diminished compared to NT90 surfaces. Thus, surface roughness is 
another important parameter to tune for modulating cell response, including cell spreading and 
response to inflammation. Our results show that NT90 surfaces are a promising combination of 
nanotube diameter and surface roughness to achieve an anti-restenotic phenotype in vascular 
endothelial and smooth muscle cells.  
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2.6 Conclusion 
In this study, we fabricated TiO2 nanotubes with 90 nm diameters to investigate how the 
presence of nanotube geometry affects endothelial and smooth muscle cell response, with the goal 
of designing a surface coating for bare metal stents that can decrease restenosis. We observed that 
nanotube surfaces decreased SMC coverage by decreasing both cell adhesion and cell spreading 
area. In addition, we found significant reductions in the inflammatory responses of both cell types 
cultured on nanotubes compared to unmodified surfaces: TiO2 nanotube surfaces attenuated 
TNFα-induced SMC proliferation, as well as TNFα-induced EC adhesion molecule expression. 
Further, we compared the 90 nm nanotubes with 30 nm and 50 nm nanotubes and found that 90 
nm nanotubes led to the greatest decrease in SMC coverage and inflammatory response. Taken 
together, we show that TiO2 nanotube surface coatings on stents are a promising alternative to 
DES for decreasing restenosis.   
 
2.7 Acknowledgements, and Disclosures  
 We acknowledge research support from the Alfred Mann Institute, the National Institutes 
of Health, and the National Science Foundation Graduate Research Fellowship.  
 Thank you to Dr. Frances Allen at the UC Berkeley Biomolecular Nanotechnology center 
for advice and assistance with helium ion microscopy data acquisition. Thank you to the staff at 
the UC Berkeley Electron Microscope Laboratory for assistance with sample preparation. We 
gratefully acknowledge the use of the JPK Instruments AFM and supporting equipment at SF 
State. The JPK Instruments AFMs and supporting facilities were obtained under NSF MRI award 
# NSF MRI award #1626611. We would also like to thank Kayla Wolf and Katie Cabral for their 
scientific input and advice during this study. 
54 
 
2.8 References  
[1] C. P. Regan et al., “Molecular mechanisms of decreased smooth muscle differentiation 
marker expression after vascular injury,” J. Clin. Invest., vol. 106, no. 9, pp. 1139–1147, 
Nov. 2000. 
[2] V. J. Dzau, R. C. Braun-Dullaeus, and D. G. Sedding, “Vascular proliferation and 
atherosclerosis: New perspectives and therapeutic strategies,” Nat. Med., vol. 8, no. 11, 
pp. 1249–1256, Nov. 2002. 
[3] A. Cuneo and M. Autieri, “Expression and Function of Anti-Inflammatory Interleukins: 
The Other Side of the Vascular Response to Injury,” Curr. Vasc. Pharmacol., vol. 7, no. 3, 
pp. 267–276, Jul. 2009. 
[4] L. Denes, L. Entz, and V. Jancsik, “Restenosis and therapy.,” Int. J. Vasc. Med., vol. 2012, 
p. 406236, 2012. 
[5] I.-M. . Chung, H. K. Gold, S. M. Schwartz, Y. Ikari, M. A. Reidy, and T. N. Wight, 
“Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent 
deployment,” J. Am. Coll. Cardiol., vol. 40, no. 12, pp. 2072–2081, Dec. 2002. 
[6] C. Kaiser et al., “Drug-Eluting versus Bare-Metal Stents in Large Coronary Arteries,” N. 
Engl. J. Med., vol. 363, no. 24, pp. 2310–2319, Dec. 2010. 
[7] M. Sabate et al., “Everolimus-eluting stent versus bare-metal stent in ST-segment 
elevation myocardial infarction (EXAMINATION): 1 year results of a randomised 
controlled trial,” Lancet, vol. 380, no. 9852, pp. 1482–1490, Oct. 2012. 
[8] G. Nakazawa et al., “Delayed arterial healing and increased late stent thrombosis at culprit 
sites after drug-eluting stent placement for acute myocardial infarction patients: an 
autopsy study.,” Circulation, vol. 118, no. 11, pp. 1138–45, Sep. 2008. 
55 
 
[9] K. Katsanos, S. Spiliopoulos, P. Kitrou, M. Krokidis, and D. Karnabatidis, “Risk of Death 
Following Application of Paclitaxel-Coated Balloons and Stents in the Femoropopliteal 
Artery of the Leg: A Systematic Review and Meta-Analysis of Randomized Controlled 
Trials.,” J. Am. Heart Assoc., vol. 7, no. 24, p. e011245, Dec. 2018. 
[10] M. Shuchman, “Trading Restenosis for Thrombosis? New Questions about Drug-Eluting 
Stents,” N. Engl. J. Med., vol. 355, no. 19, pp. 1949–1952, Nov. 2006. 
[11] K. R. Kam, L. A. Walsh, S. M. Bock, J. D. Ollerenshaw, R. F. Ross, and T. A. Desai, 
“The effect of nanotopography on modulating protein adsorption and the fibrotic 
response.,” Tissue Eng. Part A, vol. 20, no. 1–2, pp. 130–8, Jan. 2014. 
[12] L. A. Walsh, J. L. Allen, and T. A. Desai, “Nanotopography applications in drug 
delivery.,” Expert Opin. Drug Deliv., vol. 12, no. 12, pp. 1823–7, 2015. 
[13] J. Kim, E. B. Schlesinger, and T. A. Desai, “Nanostructured materials for ocular delivery: 
nanodesign for enhanced bioadhesion, transepithelial permeability and sustained 
delivery.,” Ther. Deliv., vol. 6, no. 12, pp. 1365–76, 2015. 
[14] V. Uskoković and T. A. Desai, “Nanoparticulate drug delivery platforms for advancing 
bone infection therapies,” Expert Opin. Drug Deliv., vol. 11, no. 12, pp. 1899–1912, Dec. 
2014. 
[15] C. R. Zamecnik, M. M. Lowe, D. M. Patterson, M. D. Rosenblum, and T. A. Desai, 
“Injectable Polymeric Cytokine-Binding Nanowires Are Effective Tissue-Specific 
Immunomodulators,” ACS Nano, vol. 11, no. 11, pp. 11433–11440, Nov. 2017. 
[16] C. R. Zamecnik, E. S. Levy, M. M. Lowe, B. Zirak, M. D. Rosenblum, and T. A. Desai, 
“An Injectable Cytokine Trap for Local Treatment of Autoimmune Disease,” 
Biomaterials, p. 119626, Nov. 2019. 
56 
 
[17] M. K. Singh et al., “Integrated biomimetic carbon nanotube composites for in vivo 
systems,” Nanoscale, vol. 2, no. 12, p. 2855, Dec. 2010. 
[18] D. C. Miller, A. Thapa, K. M. Haberstroh, and T. J. Webster, “Endothelial and vascular 
smooth muscle cell function on poly(lactic-co-glycolic acid) with nano-structured surface 
features,” Biomaterials, vol. 25, no. 1, pp. 53–61, 2004. 
[19] T.-W. Chung, D.-Z. Liu, S.-Y. Wang, and S.-S. Wang, “Enhancement of the growth of 
human endothelial cells by surface roughness at nanometer scale,” Biomaterials, vol. 24, 
no. 25, pp. 4655–4661, Nov. 2003. 
[20] J. Park, S. Bauer, P. Schmuki, and K. von der Mark, “Narrow Window in Nanoscale 
Dependent Activation of Endothelial Cell Growth and Differentiation on TiO 2 Nanotube 
Surfaces,” Nano Lett., vol. 9, no. 9, pp. 3157–3164, Sep. 2009. 
[21] E. K. F. Yim, R. M. Reano, S. W. Pang, A. F. Yee, C. S. Chen, and K. W. Leong, 
“Nanopattern-induced changes in morphology and motility of smooth muscle cells.,” 
Biomaterials, vol. 26, no. 26, pp. 5405–13, Sep. 2005. 
[22] P. Roy, S. Berger, and P. Schmuki, “TiO2 Nanotubes: Synthesis and Applications,” 
Angew. Chemie Int. Ed., vol. 50, no. 13, pp. 2904–2939, Mar. 2011. 
[23] L. Peng, M. L. Eltgroth, T. J. LaTempa, C. A. Grimes, and T. A. Desai, “The effect of 
TiO2 nanotubes on endothelial function and smooth muscle proliferation,” Biomaterials, 
vol. 30, no. 7, pp. 1268–1272, 2009. 
[24] H. Nuhn, C. E. Blanco, and T. A. Desai, “Nanoengineered Stent Surface to Reduce In-
Stent Restenosis in Vivo,” ACS Appl. Mater. Interfaces, vol. 9, no. 23, pp. 19677–19686, 
Jun. 2017. 
[25] K. Noda, J. Zhang, S. Fukuhara, S. Kunimoto, M. Yoshimura, and N. Mochizuki, 
57 
 
“Vascular endothelial-cadherin stabilizes at cell-cell junctions by anchoring to 
circumferential actin bundles through alpha- and beta-catenins in cyclic AMP-Epac-Rap1 
signal-activated endothelial cells.,” Mol. Biol. Cell, vol. 21, no. 4, pp. 584–96, Feb. 2010. 
[26] T. Suzuki et al., “Stent-Based Delivery of Sirolimus Reduces Neointimal Formation in a 
Porcine Coronary Model,” Circulation, vol. 104, no. 10, pp. 1188–1193, Sep. 2001. 
[27] F. G. P. Welt and C. Rogers, “Inflammation and Restenosis in the Stent Era,” Arterioscler. 
Thromb. Vasc. Biol., vol. 22, no. 11, 2002. 
[28] P. S. Monraats et al., “Tumor necrosis factor-α plays an important role in restenosis 
development,” FASEB J., vol. 19, no. 14, pp. 1998–2004, Dec. 2005. 
[29] C. Lawson and S. Wolf, “ICAM-1 signaling in endothelial cells.,” Pharmacol. Rep., vol. 
61, no. 1, pp. 22–32. 
[30] J. M. Cook-Mills, M. E. Marchese, and H. Abdala-Valencia, “Vascular Cell Adhesion 
Molecule-1 Expression and Signaling During Disease: Regulation by Reactive Oxygen 
Species and Antioxidants,” Antioxid. Redox Signal., vol. 15, no. 6, pp. 1607–1638, Sep. 
2011. 
[31] P. Heider, M. G. Wildgruber, W. Weiss, H. J. Berger, E. H. Henning, and O. Wolf, “Role 
of adhesion molecules in the induction of restenosis after angioplasty in the lower limb,” 
J. Vasc. Surg., vol. 43, no. 5, pp. 969–977, May 2006. 
[32] S. Bayata, E. Arikan, M. Yesil, N. Postaci, A. Tas, and M. Koseoglu, “An important role 
for VCAM-1, but not for ICAM-1 in restenosis following coronary stent implantation,” 
Anadolu Kardiyol. Dergisi/The Anatol. J. Cardiol., vol. 10, no. 5, pp. 405–409, Oct. 2010. 
[33] S. Choi et al., “TNF-α elicits phenotypic and functional alterations of vascular smooth 
muscle cells by miR-155-5p-dependent down-regulation of cGMP-dependent kinase 1.,” 
58 
 
J. Biol. Chem., vol. 293, no. 38, pp. 14812–14822, Aug. 2018. 
[34] R. Davis, S. Pillai, N. Lawrence, and S. P. Chellappan, “TNF-α-mediated proliferation of 
vascular smooth muscle cells involves Raf-1-mediated inactivation of Rb and transcription 
of E2F1-regulated genes,” Cell Cycle, vol. 11, no. 1, pp. 109–118, Jan. 2012. 
[35] S. Zhong et al., “Effects of polydopamine functionalized titanium dioxide nanotubes on 
endothelial cell and smooth muscle cell,” Colloids Surfaces B Biointerfaces, vol. 116, pp. 
553–560, 2014. 
[36] A. Farb et al., “Extracellular matrix changes in stented human coronary arteries,” 
Circulation, vol. 110, no. 8, pp. 940–947, 2004. 
[37] R. Kornowski, M. K. Hong, F. O. Tio, O. Bramwell, H. Wu, and M. B. Leon, “In-Stent 
Restenosis: Contributions of Inflammatory Responses and Arterial Injury to Neointimal 
Hyperplasia,” J. Am. Coll. Cardiol., vol. 31, no. 1, pp. 224–230, Jan. 1998. 
[38] A. Farb et al., “Pathology of Acute and Chronic Coronary Stenting in Humans,” 
Circulation, vol. 99, no. 1, pp. 44–52, Jan. 1999. 
[39] S. Oguchi et al., “Monoclonal Antibody Against Vascular Cell Adhesion Molecule-1 
Inhibits Neointimal Formation After Periadventitial Carotid Artery Injury in Genetically 
Hypercholesterolemic Mice,” Arterioscler. Thromb. Vasc. Biol., vol. 20, no. 7, pp. 1729–
1736, Jul. 2000. 
[40] Y. Qu et al., “VCAM-1 siRNA reduces neointimal formation after surgical mechanical 
injury of the rat carotid artery,” J. Vasc. Surg., vol. 50, no. 6, pp. 1452–1458, Dec. 2009. 
[41] E. Mori et al., “Essential Role of Monocyte Chemoattractant Protein-1 in Development of 
Restenotic Changes (Neointimal Hyperplasia and Constrictive Remodeling) After Balloon 
Angioplasty in Hypercholesterolemic Rabbits,” Circulation, vol. 105, no. 24, pp. 2905–
59 
 
2910, Jun. 2002. 
[42] P. W. Bryant, Q. Zheng, and K. M. Pumiglia, “Focal adhesion kinase is a phospho-
regulated repressor of Rac and proliferation in human endothelial cells.,” Biol. Open, vol. 
1, no. 8, pp. 723–30, Aug. 2012. 
[43] E. A. Cavalcanti-Adam, T. Volberg, A. Micoulet, H. Kessler, B. Geiger, and J. P. Spatz, 
“Cell Spreading and Focal Adhesion Dynamics Are Regulated by Spacing of Integrin 
Ligands,” Biophys. J., vol. 92, no. 8, pp. 2964–2974, Apr. 2007. 
[44] ‡ Cynthia A.  Reinhart-King, § and Micah  Dembo, and ‡ Daniel A.  Hammer*, 
“Endothelial Cell Traction Forces on RGD-Derivatized Polyacrylamide Substrata†,” 2002. 
[45] I. M. Tolić-Nørrelykke and N. Wang, “Traction in smooth muscle cells varies with cell 
spreading,” J. Biomech., vol. 38, no. 7, pp. 1405–1412, Jul. 2005. 
[46] F. Wang et al., “Reciprocal interactions between beta1-integrin and epidermal growth 
factor receptor in three-dimensional basement membrane breast cultures: a different 
perspective in epithelial biology.,” Proc. Natl. Acad. Sci. U. S. A., vol. 95, no. 25, pp. 
14821–6, Dec. 1998. 
[47] Z. Mostafavi-Pour, J. A. Askari, S. J. Parkinson, P. J. Parker, T. T. C. Ng, and M. J. 
Humphries, “Integrin-specific signaling pathways controlling focal adhesion formation 
and cell migration,” J. Cell Biol., vol. 161, no. 1, p. 155, Apr. 2003. 
[48] G. Le Saux et al., “Spacing of Integrin Ligands Influences Signal Transduction in 
Endothelial Cells,” Biophys. J., vol. 101, no. 4, pp. 764–773, Aug. 2011. 
[49] G. Le Saux, A. Magenau, T. Böcking, K. Gaus, and J. J. Gooding, “The Relative 
Importance of Topography and RGD Ligand Density for Endothelial Cell Adhesion,” 
PLoS One, vol. 6, no. 7, p. e21869, Jul. 2011. 
60 
 
[50] W. Chen, Y. Shao, X. Li, G. Zhao, and J. Fu, “Nanotopographical Surfaces for Stem Cell 
Fate Control: Engineering Mechanobiology from the Bottom.,” Nano Today, vol. 9, no. 6, 
pp. 759–784, Dec. 2014. 
[51] M. Arnold et al., “Activation of Integrin Function by Nanopatterned Adhesive Interfaces,” 
ChemPhysChem, vol. 5, no. 3, pp. 383–388, Mar. 2004. 
 
 
  
61 
 
Recent advances in intraocular sustained-release drug delivery devices 
 
3.1 Abstract 
Topical eye-drop administration and intravitreal injections are the current standard for 
ocular drug delivery. However, patient adherence to the drug regimen and insufficient 
administration frequency are well-documented challenges to this field. In this review, we 
describe recent advances in intraocular implants designed to deliver therapeutics for months to 
years, in order to obviate the issues of patient adherence. We highlight recent advances in 
monolithic ocular implants in literature, the commercialization pipeline, and approved for the 
market. We describe design considerations based on material selection, active pharmaceutical 
ingredient, and implantation site.  
 
3.2 Introduction  
Elderly populations have increased incidences of ocular disease [1], [2], and as life 
expectancy increases, the burden of managing and treating ocular disease will become more 
prevalent [3]. Many ocular diseases have striking impacts to vision that significantly impact 
quality of life, eventually making everyday tasks difficult to impossible.  
Therapeutic treatment of ocular disease falls into two primary modalities: topical drops or 
intravitreal injections. Topical drops have been a mainstay for decades. Specific to asymptomatic 
disease, such as glaucoma, compliance is a major challenge to efficacious therapy: a review 
across 5 studies showed an average of only 67% of glaucoma patients sustained their therapeutic 
schedule after one year [4]. 
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Intraocular injections were the first effective back-of-the-eye therapy, most notably with 
the approval of ranibizumab (Lucentis®, Genentech, Inc.) and the subsequent approval of 
aflibercept (EYLEA®, Regeneron Pharmaceuticals) for treatment of wet age-related macular 
degeneration (wAMD). However, recent retrospective studies observed that real-world use and 
injection frequency did not replicate trial outcomes, largely due to insufficient administration 
frequency [5]. 
The first commercial examples of implantable intraocular devices were surgically 
implanted reservoir-based devices introduced via pars plana incision and sutured to the sclera for 
long-term residence within the eye.  These devices (e.g. Vitrasert® for cytomegalovirus or 
Retisert® for non-infectious uveitis) release a small molecule therapeutic over the course of 
months to years [6], [7]. The subsequent generation of devices aimed to reduce the procedural 
invasiveness by introducing the device with a custom injector. Both degradable (e.g. Ozurdex®) 
and non-degradable (e.g. Iluvien®) versions became commercially available, where the rod-
shaped implants are deployed by piston or fluid [8], [9]. To date, commercial intraocular devices 
have relied on small molecule therapeutics, leaving a significant opportunity in highly 
efficacious protein-based delivery technologies.  
Despite some successes in device development, novel treatments that could supplant 
topical drops and intravitreal injection remain poised to advance treatment of ocular disease. 
External devices provide a means to maintain the minimally invasive advantage of topical drops, 
while providing a sustained release solution [10]. Alternatively, particle technologies are suitable 
for deployment via the familiar intravitreal injection, while providing an extended duration of 
therapeutic activity [11], [12]. In this review we will focus on a final class of sustained delivery 
devices that are monolithic and implanted intraocularly, which may be introduced via custom 
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injector or by surgical intervention.  We will discuss recent advances in implantable intraocular 
devices, covering design considerations based on drug type, and means of delivering devices and 
final implantation site, as well as commercial and pipeline device development. 
 
3.3 Material Selection 
The material selection for long-acting, sustained release implants is critical for tuning the 
release kinetics, degradation rate, and biocompatibility. Both biodegradable and 
nonbiodegradable materials have been used for ocular drug delivery implants reported in 
literature and currently on the market. This section covers the commonly used materials for 
ocular drug delivery, including their tunability, biocompatibility, and degradation kinetics. 
3.3.1 Non-biodegradable polymers 
Non-biodegradable implants are commonly used for the first generation of ocular drug 
delivery implants. This includes Retisert® and Vitrasert®, which consist of drug tablets coated 
with non-biodegradable polymers. Commonly used non-degradable materials include polyvinyl 
alcohol (PVA), ethylene-vinyl acetate (EVA), and silicones. In Retisert®, the drug tablet is 
coated with a nonpermeable silicone featuring an orifice to allow drug release. Between the 
silicone orifice and the tablet, there is a permeable PVA membrane to control the rate of 
diffusion through the orifice. Vitrasert® employs a similar concept of diffusion-limited drug 
release through the orifice of a nonpermeable coating. Vitrasert® consists of a tablet first coated 
with PVA, followed by a nonpermeable, discontinuous EVA coating, which is then covered by a 
second coating of PVA. Other non-biodegradable implants in the market, such as Iluvien® 
(Alimera Sciences, Inc), consist of a polyimide tube loaded with a drug-PVA matrix, and capped 
on one end with a silicone adhesive. Another non-degradable material is crosslinked 
64 
 
poly(ethylene glycol) (PEG). For example, PEGDA, a photo-crosslinkable PEG hydrogel, has 
been reported to release triamcinolone acetonide and ovalbumin, a model protein [13].   
Non-biodegradable implants have the advantage of achieving very long-term release and 
have demonstrated good biocompatibility [14]. However, upon drug depletion, the reservoir 
material either requires surgical removal or remains at the implantation site. In recent years, 
focus has shifted toward using biodegradable polymers for ocular implants. 
3.3.2 Biodegradable polymers   
Biodegradable or erodible polymers have been increasingly used in implants both in 
academic research and on the market. They have the advantage of eroding after drugs are 
released to avoid the need for surgical removal. Their degradation kinetics can also be tuned by 
material composition. 
Commonly used biodegradable polymers include poly(lactic-co-glycolic acid) (PLGA) 
and poly(caprolactones) (PCL). The most widely used in both literature and commercially is 
PLGA. It can be engineered to achieve sustained release for several small molecules [15]–[17]. 
Commercially, PLGA is co-extruded with dexamethasone in Ozurdex® (Allergan) to achieve 6 
months of drug delivery.  
A limitation of PLGA is the formation of inflammatory degradation products. PLGA 
degrades into lactic acid and glycolic acid, which create a highly acidic environment [18] and 
cause local inflammatory reactions [19]. In one study, PLGA scaffolds were implanted 
subcutaneously into rats to observe host-tissue responses after 2 weeks. The authors observed 
significant host cell and macrophage accumulation near the PLGA scaffold, indicative of a 
severe inflammatory reaction [19]. These inflammatory effects are alleviated in implants that 
65 
 
release anti-inflammatory steroids, such as the case of Ozurdex® (described later). However, 
when releasing other drugs, the inflammatory responses may cause problematic reactions. 
Polycaprolactone (PCL) is another biodegradable polymer that has been demonstrated in 
ocular drug delivery implants in literature. Like PLGA, PCL can be engineered to have highly 
tunable release kinetics and is easily fabricated into thin films by draw or spin casting polymer 
solutions. Studies of PCL in the eye have not elicited significant immunologic responses [20]–
[22]. PCL degradation kinetics are slower than that of PLGA but can be tuned by adjusting the 
polymer molecular weight [23], [24].  
While PEG itself is not degradable, it can be conjugated to and crosslinked by 
biodegradable linkers to form an absorbable material. In-situ forming PEG-based implants are 
under development by Ocular Therapeutix to deliver tyrosine kinase inhibitors (TKI) 
(NCT03630315). Polyorthoesters (POEs) and polyanhydrides are other materials used, though 
they have not been actively used commercially or in literature in recent years. 
 
3.4 Design considerations based on drug type  
3.4.1 Sustained delivery of small molecules  
Most of the ophthalmic drug delivery technologies are currently targeted towards 
sustained delivery of small molecule therapeutics over the course of several months to years. 
Small molecules are conventionally delivered via eye drops and may require several 
administrations per day. A sustained-release implant would obviate the need for daily patient 
administration in favor of device implantation every few months or years. Drugs can also be co-
extruded within polymer matrices to achieve long-term release with desired release kinetics. 
Release kinetics can be dissolution- [20] or solubility-limited [21] and depend on drug and 
66 
 
polymer properties, including partition coefficient, LogP, molecular weight, and drug solubility 
[25]. Both zero-order and first-order release profiles have been demonstrated [25]–[27], and 
release rate can be tuned by surface area and film thickness. The release duration is dependent on 
the amount of drug within the reservoir and the polymeric membranes degradation kinetics.  
Within the past 2 years, PLGA has been used for the sustained release of small molecules 
including etoposide [16], lupeol [15], and clindamycin hydrochloride [17] (Table 3.1) with a 
release duration on the order of months. Since PLGA undergoes both bulk degradation and 
surface degradation [23], the release kinetics of long-acting implants may change during the 
course of polymer degradation. PLGA can also be formulated as a suspension with the drug of 
interest and a biocompatible solvent (e.g. N-methyl-2-pyrrolidone) that can be injected and 
formed in situ. In situ forming PLGA implants have been used to release triamcinolone acetonide 
[28] and dexamethasone [29], achieving 42 days and 1 week of sustained release respectively in 
vitro. In in situ-forming implants, polymer concentration can be tuned to achieve desired release 
kinetics. PCL thin-film ocular drug delivery devices have demonstrated in vivo release of 
rapamycin for 16 weeks [26] and omidenapag isopropyl (DE-117) for 24 weeks [30].  Since PCL 
degradation is much slower, drug release kinetics can be decoupled from polymer degradation 
kinetics.  
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3.4.2 Sustained delivery of proteins and biologics  
Biopharmaceuticals including proteins and peptides have shown great promise as novel 
therapeutics in the treatment of ocular diseases. Unlike small molecules, biologics have high 
potency and activity, low nonspecific binding, as well as lower toxicity and drug-drug 
interactions. With the approval of anti-VEGF therapeutics such ranibizumab (Lucentis®; 
Genentech, California), the market for ocular biopharmaceuticals is rapidly growing. However, 
patient compliance to monthly intravitreal injections has been a major hurdle with these 
treatments. In a recent study, 39.8% of AMD patients showed inadequate compliance to Lucentis 
treatment and follow-up [31]. Anti-VEGF therapies requiring less frequent injections are 
available (Aflibercept; Regeneron Pharmaceuticals), or under development (Abicipar; Allergan). 
Nevertheless, there is an urgent need for the development of suitable ocular delivery systems for 
biologics to alleviate patient compliance concerns. Biologics offer many delivery challenges due 
to their high molecular weight, hydrophilicity, degradation, short half-life, and poor permeability 
across epithelial barriers [32], [33]. Therefore, novel delivery systems are needed to enable the 
delivery of biologics to ocular tissues.  
Much of the focus in protein drug delivery has been on gel-based formulations and 
reservoir systems. Gel-based formulations consist of liquid or injectable semi-solids with protein 
suspended in organic solvent that solidify upon injection [33]. The rate and duration of release is 
influenced by the gelling rate as well as implant porosity, polymer molecular weight, and 
solvent. Badiee et al. used chitosan nanoparticles embedded in a matrix of hyaluronic acid and 
zinc sulfate to provide long-term sustained release of becavizumab [34]. They showed this 
system enhanced sustained release compared to bevacizumab particles. Another study used a 
69 
 
porous polydimethylsiloxane/polyvinyl alcohol composite drug delivery system to deliver 
infliximab for 3 months in rabbits after an ocular burn [35].    
For membrane-based reservoir systems, nonporous membranes used for delivering small 
molecules do not allow for the diffusion of larger proteins. Macroporous membranes fabricated 
by mixing porogens with a polymer would allow diffusion of proteins, but cannot achieve zero-
order release. In order to achieve sustained, zero-order release of proteins, nanoporous PCL thin 
films were engineered with pore sizes on the order of the diffusing molecule size [36]. This 
nanoporous PCL thin film device was capable of delivering ranibizumab for 12 weeks in vivo 
without exhausting the initial drug payload [26]. Furthering thin film devices, a methodology 
was developed for design of such devices that utilized a PEG formulation to control protein 
solubility [37]. The corresponding devices can be engineered to achieve desired protein stability 
and release rate. The devices studied released aflibercept over the course of 11 weeks in vitro, 
and devices were well-tolerated in African green monkeys. 
The Genentech/Forsight Vision 4 Port Delivery System is another reservoir device for 
delivering ranibizumab. The device is a scleral plug consisting of a reservoir, a semi-permeable, 
non-biodegradable membrane, and a port used to reload drug into the reservoir. Initial drug 
loading typically limits the total drug release duration and device lifetime and the refillable port 
was developed to address this challenge. The implant has been loaded with ranibizumab for the 
treatment of wAMD, and device is designed to last at least 6 months between refills [38].  
With long-acting delivery systems for biologics, understanding the stability of the protein 
or biologic of interest at physiological temperature is essential. Proteins can undergo structural 
changes or degradation that lead to loss of biological activity over time. Biologics in long-acting 
implants can be engineered or formulated to be stable for the required release duration. In some 
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cases, using solubility-limiting excipients can improve protein stability, such as PEG in an 
aflibercept-eluting thin-film device [37].  However, due to the unique nature of each biologic, 
particularly antibodies, there is no single formulation that can effectively improve stability for all 
biologics [39]. Therefore, a thorough understanding of the possible degradation mechanisms for 
a particular biologic is necessary for their success in sustained-delivery systems.  
Despite many advances, to date no ophthalmic biodegradable implant has been approved 
for biopharmaceutical drugs. With the large and growing numbers of protein and large molecule 
therapeutics under clinical trials, there remains an urgent need to develop new methods to deliver 
these highly potent biologics in a controlled and long-term manner.  
3.4.3 Cells-based implants  
Cell encapsulation is a novel way to deliver large compounds to tissues for an extended 
period of time. Neurotech Pharmaceuticals uses a unique customized NTC-200 cell line derived 
from normal human retinal pigment epithelial cells. These cells are engineered to have low 
metabolic activity, increasing likelihood of survival in the vitreous. The cells can also be 
genetically transfected to secrete therapeutics and growth factors. The cells are incorporated into 
a polymeric device that is surgically implanted in the vitreous, and the ocular implant enables 
continuous production and release of therapeutic proteins to the eye for over 2 years. The device 
isolates the cells from the vitreous while simultaneously allowing influx of nutrients. Their 
investigational treatment, NT-501 ECT, provides intravitreal sustained release of soluble ciliary 
neurotrophic factor (CNTF) receptor. The device was well-tolerated but achieved limited 
efficacy in treating retinitis pigmentosa (RP) [40], [41] and geographic atrophy (GA) [42]. 
Neurotech is now applying NT-501 in clinical studies for the treatment of glaucoma 
(NCT02862938) and macular telangectasia (MacTel) (NCT01949324). For glaucoma, Neurotech 
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has completed Phase I trials, and phase II studies are currently underway. Phase I trials of 
MacTel showed good tolerability and safety for the device [43]. 
 
3.5 Delivery and Implantation Site Considerations   
Implantation site selection depends on the desired pharmacokinetics, biocompatibility, 
and clinical considerations. An implantation site closer to the target tissue can achieve a high 
concentration of drug in the target tissue. Drugs may diffuse from the anterior chamber to the 
posterior chamber by convection and normal movements, though the kinetics depend on the 
chemistry of the drug [44]. However, drug distribution between the anterior to the posterior 
segment may be hindered by aqueous flow, clearance to the blood, and the physical barrier of the 
iris, lens, and ciliary body. Pharmacokinetics of drug transport to various tissues in the eye must 
be tested for a particular drug and implantation location.  
Common methods of implantation are intravitreal injection, subconjunctival delivery 
[45], and intracameral implantation via incision [27], [45].The most attractive route for delivery 
to the vitreous is via injection, as it duplicates the standard-of-care for existing anti-VEGF 
therapeutics. Implantable devices can be injected at the pars plana, which is located posterior to 
the lens and anterior to the retina. At this location in the vitreous, implant position can be 
controlled to be out of the visual axis. However, intravitreal implants can risk retinal detachment 
and endophthalmitis [46] as well as vitreous hemorrhage, cystoid macular edema, and formation 
of tenacious epiretinal membranes [47]. Placement is also critical for intracameral implants due 
to the risk of blocking vision. Development of cataracts due to contact with the lens, or damage 
to the corneal epithelium [27] are also potential risks. Subconjunctival implantation has also been 
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explored for Ozurdex®, and the implants were well-tolerated in the 2-month study in patients 
with open-angle glaucoma [48]. 
The injection needle also affects clinical outcomes. Standard intravitreal injections of 
Lucentis® or EYLEA® use 30-gauge needles, but drug delivery devices require larger gauge 
needles, such as 22- and 25-gauge for Ozurdex® and Iluvien®. Larger needles do not necessarily 
lead to more pain. A study showed that patients receiving 22-gauge injections had similar pain 
scores to those receiving 29-gauge injections [49]. The shape and size of the needle can also be 
optimized to improve clinical outcomes. An Ozurdex® study showed that optimizing needle 
shape can reduce required penetration force, improve the wound architecture, and increase ease 
of injection [50].  
 
3.6 Implantable ocular drug delivery devices on the market or in the commercialization 
pipeline 
3.6.1 Recently Approved Implants 
The number of companies developing ocular drug delivery implants has skyrocketed over 
the past decade.  Products in various stages of development are being investigated for indications 
such as glaucoma, macular degeneration, diabetic macular edema, and uveitis.  
 Vitrasert® and Retisert® have been widely reviewed since their approvals in 1996 and 
2004. Since then, Ozurdex®, Iluvien®, Yutiq®, and DEXYCU® have been approved for 
sustained-release intraocular drug delivery (Table 3.2). Iluvien® (Alimera) is a non-erodible  
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implant that is injected intravitreally and achieves sustained release of FA for over three years. It 
was approved in 2014 for the treatment of DME in patients who have been previously treated 
with a course of corticosteroids and did not have a clinically significant rise in intraocular 
pressure. Similarly, Yutiq® (EyePoint Pharmaceuticals, Watertown, MA), is a polyimide non-
bioerodible intravitreal micro-insert releasing FA over 36 months. It received FDA approval in 
October 2018 for treatment of chronic noninfectious uveitis affecting the posterior segment of 
the eye.  
Biodegradable implants offer some advantages over reservoir systems. In addition to the 
ability to be tuned to change release rates based on drug properties, they eliminate the need for 
extraction and thereby decrease the risk associated with surgery.  
The first sustained-release biodegradable steroid implant, Ozurdex®, was developed by 
Allergan and approved in 2009 for treatment of macular edema following vein occlusion and 
noninfectious posterior uveitis. The intravitreal implant is made of PLGA co-extruded with 
dexamethasone. It is placed in the vitreous through the pars plana by needle injection and 
releases peak doses of dexamethasone for 2 months followed by a lower dose for an additional 4 
months. Since its approval, many studies have investigated the efficacy of Ozurdex® for 
treatment of other indications such as uveitis and diabetic macular edema [51], [52] as well as 
trying to find ways to mitigate adverse effects of the implant such as elevated IOP [53]. 
Another recently approved intraocular drug delivery system uses the EyePoint 
Pharmaceuticals (previously Icon Biosciences, Inc) Verisome technology, an injectable 
suspension that allows sustained release of small molecules. DEXYCU® (Icon Biosciences, Inc) 
is dexamethasone suspension in acetyl triethyl citrate, and was approved in 2018 for treatment of 
postoperative inflammation. The suspension is injected into the posterior chamber of the eye, 
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where gel settles into a small sphere and slowly degrades [54]. The release duration of 
dexamethasone is between 2-3 weeks (NDA 208912). In clinical trial controlled by placebo, 
DEXYCU® led to a 2- to 3-fold increase in the proportion of patients with clearing of anterior 
chamber cells, and a lower proportion of patients requiring rescue medications (NCT02006888).  
3.6.2 Implants in the Pipeline 
Intraocular drug delivery implants that are currently in clinical trials are summarized in 
Table 3.3. Allergan is currently working on the development of a brimonidine tartrate intravitreal 
implant (Brimo PS DDS®) in patients with geographic atrophy due to age-related macular 
degeneration. The implant is currently in phase II clinical trials (NCT01080209). Allergan 
reported functional recovery after implantation of the Brimo PS DDS® system in a rabbit model 
of retinal ganglion cell degeneration [55]. Additionally, the implant enhanced spatial acuity in a 
non-human primate model of chronic glaucoma [56]. However, it remains to be seen whether 
inflammation due to PLGA degradation products, which may be masked in Ozurdex® as it 
delivers an anti-inflammatory agent, would become an issue in the brimonidine implant.  
The Genentech/ForSight Vision4 Port Delivery System (PDS), as mentioned above, is a 
non-biodegradable, refillable reservoir device designed to deliver ranibizumab for treatment of 
wAMD. The refillable port is designed to extend the effective lifetime of the reservoir by 
delivering additional therapeutic doses when drug in the reservoir depletes. Phase II results 
showed that 80% of PDS patients who received a 100 mg/mL dose can go at least six months 
between refills, while achieving similar visual acuity outcomes as monthly ranibizumab 
injections [38]. Genentech is currently planning Phase III clinical trials. 
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Ocular Therapeutix uses a hydrogel-based formulation technology for treating various 
eye diseases. OTX-TIC is a bioresorbable intracameral implant containing micronized travoprost 
with a target delivery duration of four to six months and is intended for patients with glaucoma. 
A study in beagle dogs showed that the implant was well-tolerated and released travoprost with 
zero-order release kinetics for 4 months [57]. Additionally, a sustained-release tyrosine kinase 
inhibitor (TKI) implant is under development in Phase I trials [53]. The implant is ad 
bioresorbable hydrogel that contains TKI particles in an injectable fiber, designed for intravitreal 
injection for a release duration of up to 12 months. Ocular Therapeutix is also collaborating with 
Regeneron Pharmaceuticals to developing a sustained-release implant for aflibercept 
(EYLEA®). The device, OTX-IVT is intended to reduce the frequency of injections to once 
every 4-6 months (ocutx.com) and is in preclinical development.  
 
3.7 Conclusion 
To date, the only successfully marketed implantable devices release small molecules, 
either an antiviral or a corticosteroid, and have focused on implantation in the vitreous. With 
increased acceptance of stent/shunt deployment for glaucoma treatment, the field will likely see 
new devices enter the anterior segment. The majority of existing devices are non-degradable, but 
their use is limited by the device therapeutic duration and requires retrieval or abandonment of 
depleted devices. For biodegradable devices, PLGA has been successfully employed in 
Ozurdex®; however, the inflammatory nature of PLGA may limit wide-spread tolerability of 
PLGA in intraocular applications beyond delivery of anti-inflammatory drugs.  
A significant need exists to deliver protein therapeutics for treating back-of-the-eye 
diseases. The Port Delivery System (PDS) is poised to be the first protein delivery system within 
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the eye, and early trial results indicate significantly extended duration between drug 
administration. However, there are substantial potential complications, and the required surgical 
device placement may not be suitable for all patients. An injectable device that only requires 
administration 2-3 times per year would be a notable advance in ocular drug delivery devices, 
particularly if constructed from biodegradable materials. A self-coiling device is compelling as it 
can be injected and subsequently occupy limited space within the vitreous. An in-situ gel-based 
depot or reservoir-based thin film device are other promising approaches for an injectable 
biodegradable system for protein delivery, which may expand the competitive landscape in the 
coming years. While drug delivery to the eye will continue to be a difficult therapeutic area, 
intraocular device development has remained a source of continued innovation, and ongoing 
commercial successes are expected to open the field to further acceptance and adoption of novel 
drug delivery technologies. 
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Co-delivery of Timolol and Brimonidine with a Polymer Thin-film Intraocular 
Device  
 
4.1 Abstract 
 PURPOSE. We developed a polycaprolactone (PCL) co-delivery implant that achieves zero-
order release of two ocular hypotensive agents, timolol maleate and brimonidine tartrate. We 
also demonstrate IOP-lowering effects of the implant for three months in vivo.  
METHODS. Two PCL thin-film compartments were attached to form a V-shaped co-delivery 
device using film thicknesses of approximately 40 μm and 20 μm for timolol and brimonidine 
compartments, respectively. In vitro release kinetics were measured in pH- and temperature-
controlled fluid chambers. Empty or drug-loaded devices were implanted intracamerally in 
normotensive rabbits for up to 13 weeks with weekly measurements of intraocular pressure 
(IOP). For ocular concentrations, rabbits were euthanized at 4, 8, or 13 weeks, aqueous fluid was 
collected and ocular tissues dissected. Drug concentrations were measured by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS).  
RESULTS. In vitro studies show zero-order release kinetics for both timolol (1.75 µg/day) and 
brimonidine (0.48 µg/day) for up to 60 days. In rabbit eyes, the device achieved an average 
aqueous fluid concentration of 98.1 {plus minus} 68.3 ng/mL for timolol and 5.5 {plus minus} 
3.6 ng/mL for brimonidine. Over 13 weeks, the drug-loaded co-delivery device resulted in a 
statistically significant cumulative reduction in IOP compared to untreated eyes (p<0.05) and 
empty-device eyes (p<0.05).  
CONCLUSIONS. The co-delivery device demonstrated a zero-order release profile in vitro for 
two hypotensive agents over 60 days. In vivo, the device led to significant cumulative IOP 
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reduction of 3.4 {plus minus} 1.6 mmHg over 13 weeks. Acceptable ocular tolerance was seen, 
and systemic drug levels were unmeasurable. 
 
4.2 Introduction  
Glaucoma is one of the leading causes of irreversible blindness worldwide[1]. While 
glaucoma is most commonly treated with hypotensive eye drops to control intraocular pressure 
(IOP), the barriers to patient compliance are well-documented [2], [3], [4] with non-adherence to 
prescribed eye drops among glaucoma patients of 20-60% [2], [5]–[7].  
To circumvent problems with topical eye drop therapies, there has been substantial effort 
in developing a sustained release formulation for glaucoma therapy. For example, delivery of 
timolol maleate or brimonidine tartrate has been explored in the forms of microspheres [8], [9], 
[10], nanovesicles [11], ocular inserts [12], contact lenses [13], and others. Furthermore, a recent 
study demonstrated that sustained release of dorzolamide via biodegradable microparticles not 
only reduced IOP in normotensive rabbits [14], but also decreased glaucomatous retinal ganglion 
cell loss in a rat disease model of glaucoma [15]. We also have previously demonstrated that 
biodegradable polycaprolactone (PCL) intracameral devices delivering a prostaglandin analog 
[16], [17] attained over 5 months of IOP reduction in normotensive rabbits[16]. 
Simultaneous long-term delivery of multiple glaucoma agents would offer an advance in 
patient treatment. Managing glaucoma with two or more agents for additive or synergistic IOP 
reduction is common practice, for which a number of topical drug combination formulations 
have been developed, such as Combigan (Allergan, Dublin, Ireland) combining timolol 
maleate and brimonidine tartrate, and CosoptPF- (Akorn, Lake Forest, IL), combining 
dorzolamide HCl and timolol maleate. For sustained release devices, effectively delivering 
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multiple agents can be challenging, because different drugs often require tailored release rates. 
We optimized the thickness of diffusion-limiting PCL films to achieve customized controlled 
release rates of timolol maleate and brimonidine tartrate using a single device. Here, we report 
the design and characterization of a co-delivery implant, demonstrating customizable zero-order 
release kinetics of both drugs. We also show pharmacokinetic profiles of co-delivery devices in 
vivo and cumulative reduction in IOP using a normotensive rabbit model. 
 
4.3 Materials and Methods   
4.3.1 Materials  
All chemicals were obtained from Sigma-Aldrich Corp. (St. Louis, MO) unless noted 
otherwise. Brimonidine tartrate was obtained from Cayman Chemical (Ann Arbor, MI). 
4.3.2 Device Fabrication  
Devices were fabricated as previously described [17]. Briefly, PCL (Mn = 80 kDa) was 
dissolved in 2,2,2-trifluoroethanol at a concentration of 150 mg/mL, and spin-casted on a silicon 
wafer at 1000 RPM, then annealed at 110°C. To achieve the desired drug release rate of timolol 
and brimonidine, respectively, the film thickness was tuned for each drug compartment. Film 
thickness was measured using a film micrometer (iGaging, San Clemente, CA, USA). The 
casting process resulted in an approximately 20 µm thick film, which was used for fabricating 
the brimonidine compartment. The casting process was repeated to achieve a double layer of 
approximately 40 µm thickness, which was used to fabricate the timolol compartment. 
To make each compartment, spun-cast PCL thin films with the desired thickness were 
folded in half and heat sealed by applying current to a nichrome wire, selectively heating the 
edges (Figure 4.1, dotted lines) to form a pocket. Lyophilized timolol or brimonidine powder 
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was loaded into the pocket and heat sealed, creating a closed compartment. Each compartment is 
approximately 2 mm in width by 4 mm in length. To form the attached co-delivery device, the 
two compartments, each containing either timolol or brimonidine, were stacked together, and 
heat-sealed along one edge (Figure 4.1).  
4.3.3 In Vitro Drug Release  
The release rate of each drug-containing compartment was tested individually. The 
compartment was submerged in 0.5 mL of phosphate buffered saline (PBS) at 37°C on an orbital 
shaker. Elution medium was replaced with fresh PBS at each time point. Drug concentration was 
quantified by UV-Vis spectrometry (absorption wavelengths of timolol = 294nm and 
Figure 4.1 Schematic diagram of two-compartment device fabrication (A). To make each 
compartment, spun-cast PCL thin films were heat sealed along the edges (I) shown as dotted 
lines, and filled with either timolol maleate (orange) or brimonidine tartrate (green) (II). The 
drug-loaded compartments were sealed closed (III) and the two compartments were attached at a 
sealed edge (IV). Each compartment is about 2 mm in width by 4 mm in length. The attached 
device is shown with grains of rice for scale (B). 
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brimonidine = 254nm). The release rate was calculated by dividing the amount of drug released 
at each time point by the time passed since the previous time point.  
To verify that the process of attaching the drug compartments did not lead to defects in 
the device, drug release rate of the attached compartments was also tested as described above. 
Drug concentrations were measured using liquid chromatography with tandem mass 
spectrometry (LC-MS/MS) to separate each drug from the mixed drug solution.  
4.3.4 In Vivo Device Implantation  
Co-delivery devices were washed with 70% ethanol for 10 seconds in a sterile hood and 
subsequently dried in ambient conditions. Implantation of PCL devices in the eyes of adult male 
and female New Zealand rabbits was approved by the institutional review board and was 
performed in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and 
Vision Research. Using ophthalmic microsurgical techniques under sterile conditions in 
anesthetized rabbits, the devices were implanted in normotensive rabbit eyes as previously 
described [16], [17] with minor adjustments. A clear corneal incision was performed using a 2.4 
or 2.6mm slit knife (Alcon Laboratories, Ft. Worth, TX, USA) through which the device was 
implanted into the anterior chamber of the left eyes. An 8-0 nylon suture (Alcon Laboratories, Ft. 
Worth, TX, USA) was used to close the incision.  
Sixteen rabbits underwent surgery: 4 rabbits with drug-loaded devices at 3 time points 
(euthanized after 4, 8, and 13 weeks for analysis) and 4 rabbits with empty devices at the final 
13-week time point. Contralateral eyes were untreated and served as controls. Photos were taken 
after implantation as well as prior to euthanasia with the Canon camera body and a SLR camera-
microscope adapter (Carl Zeiss Meditec, Inc., Dublin, CA, USA). 1% prednisolone (Sandoz, 
Holzkirchen, Germany) was administered to all rabbits twice a day for 5 days and once a day for 
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5 additional days after surgery to minimize post-surgical inflammation. IOP was measured 
weekly using a handheld tonometer (TonoVet®, Icare, Vantaa, Finland). All IOP measurements 
were performed between 12 pm and 6 pm to control for high diurnal IOP fluctuations. The area 
under the curve (AUC) of baseline-subtracted IOP values was calculated using the trapezoidal 
rule over 13 weeks. The AUC of drug-loaded device treated eyes was compared to the AUC of 
untreated contralateral eyes and empty device treated eyes using a one-way ANOVA followed 
by Tukey’s multiple comparisons test to evaluate statistically significant differences among the 
AUC of the three groups. Data is presented as mean ± standard deviation.  
4.3.5 Pharmacokinetic Analysis in Rabbit Ocular Tissue 
At each endpoint, rabbits were anesthetized and 1 ml of blood was collected in lithium-
heparin tubes (BD Vacutainer®, BD, Franklin Lakes, NJ) and kept on ice until centrifugation. 
Whole blood was centrifuged at 1300 x g for 15 minutes in a refrigerated centrifuge to remove 
red blood cells from the sample. Before euthanasia, aqueous humor was withdrawn by limbal 
paracentesis using a 30-gauge needle on a 1-mL syringe. The rabbits were then euthanized by 
injecting 2 mmol/kg potassium chloride into the marginal ear vein. The ocular globe was 
enucleated immediately after euthanasia. Cornea, iris-ciliary body, vitreous and retina-choroid 
were dissected, placed in microcentrifuge tubes and frozen at -80°C until LC-MS/MS analysis.  
4.3.6 LC-MS/MS 
Brimonidine and timolol were dissolved in DMSO, mixed and further diluted in 50% 
methanol to prepare spiking solutions. The internal standard (IS) mix (brimonidine-d4 and 
timolol-d5) was prepared in the same way. Plasma, aqueous humor and vitreous samples were 
prepared using spiked standards. Analyte extraction was performed in a bullet blender (Next 
Advance, Troy, NY) at 4°C. After centrifugation at 10,000 rpm for 5 min, 75 µl of supernatant 
94 
 
was diluted with 150 µl water + 0.1% formic acid. The LC-MS/MS system consists of a 
Shimadzu LC-20AB HPLC system interfaced with QTRAP 4000 mass spectrometer (AB 
SCIEX, Redwood City, CA). LC separation was carried out on an Agilent ZORBAX SB-Phenyl 
column (50 mm × 4.6 mm, 3.5 µm) with the following mobile phase: A, LCMS grade water + 
0.1% formic acid; B, LCMS grade acetonitrile + 0.1% of formic acid. The flow rate was set at 
0.6 ml/min. Column temperature was 25ºC. The injection volume was 20 µl. Data acquisition 
and analyses were performed using the Analyst 1.6.1 software (AB SCIEX, Redwood City, CA). 
4.3.7 Histological Analysis  
For histologic studies, the empty device-implanted eyes and contralateral control eyes 
were enucleated immediately after euthanasia and submerged in 50-60 mL of Hartman's 
Fixative, and incubated for 1 day. The eyes were then transferred to 70% ethanol until 
histological analysis. Histological preparation was performed by the Gladstone Histology and 
Light Microscopy Core (San Francisco, CA, USA). Eyes were hemisected in the sagittal plane. 
Each half was paraffin-embedded, sectioned, and stained with hematoxylin and eosin (H&E). 
 
4.4 Results  
4.4.1 In Vitro Drug Release  
The average in vitro release rate of drug from the device was determined by linear 
regression on the cumulative drug released versus time. Data is presented as mean ± standard 
deviation. In vitro drug release results in Figure 4.3 show that timolol was released at a rate of 
1.75 ± 0.15 µg/day (n=3, linear regression, R2= 0.99), and brimonidine was released at a rate of 
0.48 ± 0.03µg/day (n=3, linear regression, R2= 0.98) and demonstrate zero-order release kinetics 
from each drug compartment. The drug released before the first time point is likely due to excess 
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drug powder adsorbed to the outside of the 
devices during fabrication. Attached 
compartments led to a measured drug release 
of 1.57 ± 0.55 μg/day and 0.27 ± 0.17 μg/day 
(n=3), respectively  (Figure 4.2). The 
difference in brimonidine release rate in a 
single-drug compartment (Figure 4.3) as 
compared to the released rate as part of 
attached devices (Figure 4.2) can be partly due 
to variations in device surface areas during 
fabrication. Since the devices are small and 
handmade, a slight variation of 0.25 mm in 
length and width can result in an approximately 
18-20% difference in device surface area. The 
variations in release rate may also be attributed 
to the differences in measurement method 
(UV-vis and LC-MS/MS, respectively). 
However, the release rates of attached devices and single compartments were on the same order 
of magnitude and both demonstrated a zero-order release profile.  
  
Figure 4.2 Cumulative drug release of timolol 
maleate (A) and brimonidine tartrate (B) from 
attached devices (n=3). Drug concentrations were 
measured using LC-MS/MS. Release rates were 
calculated to be 1.57 μg/day for timolol and 0.27 
μg/day for brimonidine. 
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4.4.2 In Vivo Ocular Concentrations 
Polymer co-delivery devices were successfully impl anted and tolerated in the anterior chamber 
of rabbit eyes (Figure 4.4). No signs of cataracts or ocular inflammation were observed in our 
study. However, some complications occurred due to the surgical procedure and device shape, as 
well as other unrelated medical issues. Two 8-week rabbits with drug-loaded devices 
experienced hyphema during the study period. The rabbits were prescribed 1% prednisolone 
twice a day for 3-5 days after which the condition was relieved. Three cases of anterior synechia 
Figure 4.3 Cumulative drug release (A, B) and release rates (C, D) of timolol maleate (A, C) 
and brimonidine tartrate (B, D). Linear regression fit of cumulative drug release versus time 
demonstrated zero-order release for both timolol and brimonidine. 
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were observed in two 13-week rabbits 
and one 8-week rabbit. Four cases of 
corneal neovascularization were 
observed in two 13-week rabbits an d 
two 8-week rabbits including one case 
of corneal edema. One 8-week drug-
loaded device rabbit had very low IOP 
caused by the device not being fully 
enclosed in the anterior chamber. The 
rabbit was sacrificed early as the surgery 
was incomplete and the data was not 
used for analysis. An additional 8-week 
rabbit was added to the study. LC-
MS/MS analysis of ocular tissues of 
eyes collected at different time points 
(week 4, 8, and 13) indicated sustained release of both drugs in the anterior chamber over 13 
weeks. Timolol maintained a relatively steady concentration of 98.1 ± 68.3 ng/ml in the aqueous 
humor (Figure 4.5A) with no statistically significant difference in measured concentrations at the 
three timepoints (p=0.16). Timolol concentrations in the ICB also indicated sustained release 
(Figure 4.5A). One of the 13-week rabbits showed an ICB concentration more than six times that 
of the three other rabbits, which resulted in a large standard deviation in the 13-week group. The 
average measured aqueous humor concentration for brimonidine was 5.5 ± 3.6 ng/ml. There was 
no significant difference in average aqueous humor concentrations measured at different 
Figure 4.4 Representative photos of rabbit eyes 
immediately after implantation (left column) and 
before sacrifice (right column) of empty or drug 
loaded co-delivery devices in the anterior chamber 
of the OS eyes.  
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timepoints (p=0.1). However, two of the four 13-week rabbits had non-detectable brimonidine 
concentrations in the aqueous humor (Figure 4.5B). Brimonidine ICB concentrations were low at 
all time points with an average of 0.9 ± 0.5 ng/ml. Retina choroid concentrations were below or 
close to the quantification limit for both drugs (Figure 4.5C, D). Additionally, concentrations of 
both drugs in the blood were below the limit of detection indicating that systemic levels of both 
drugs are very low. The aqueous humor concentrations in the untreated contralateral eyes were 
below quantification limit indicating no crossover effect.  
  
Figure 4.5 Concentrations of timolol maleate (A) and brimonidine tartrate (B) in relevant 
ocular tissues after 4 weeks, 8 weeks, and 13 weeks of device implantation and 
concentrations in the aqueous humor (C) and the ICB (D) of both drugs.  
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4.4.3 IOP 
IOP measurements of the device implanted eyes were compared to those of untreated, 
contralateral eyes for approximately 13 weeks after device implantation (Figure 4.6). Pre-surgery 
baseline IOP of device-implanted and contralateral eyes were 11 ± 2.1 mmHg and 9.4 ± 1.8 
mmHg, respectively. Within 7 days, the IOP of the drug-loaded device treated eyes dropped by 
4.4 ± 2.9 mmHg, while the IOP for the untreated contralateral eyes increased by 1.3 ± 2.3 
mmHg. This corresponds to an average relative drop of 37% (normalized to each rabbit’s 
baseline IOP). Over 13 weeks, the IOP of the drug-loaded device eyes decreased by 3.4 ± 1.6 
mmHg on average, whereas the IOP of the control eyes increased on average by 0.54 ± 0.97 
mmHg. Cumulative IOP reduction was evaluated by comparing the AUC of baseline-subtracted 
IOP measurements of the three groups (Figure 4.7). The drug-loaded device treated eyes resulted 
in a statistically significant cumulative reduction in IOP compared to untreated contralateral eyes 
(ANOVA with Tukey post-hoc test, p<0.01) and empty device treated eyes (p<0.05). There was 
no significant difference in cumulative IOP reduction between empty-device treated eyes and 
untreated contralateral eyes.  
 
Figure 4.6 Mean ± standard deviation of IOP change from baseline for drug-loaded eyes 
(A) and empty device eyes (B) compared to their contralateral control eyes over 91 days. 
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4.4.4 Histological Analysis after 13 weeks of Device Implantation  
Granulation tissue with a chronic inflammatory infiltrate was present at the site of 
incision in the cornea, consistent with a surgical wound. In two cases, there was corneal 
neovascularization associated with the wound (Figure 4.8C). At the site of device implantation, 
there is evidence of local mechanical disruption to the anterior iris and posterior cornea. There 
were two cases of anterior synechia (Figure 4.8E), and three cases of fibrous metaplasia due to 
the device touching the iris and corneal endothelium (Figure 4.8D). There was one case of iris 
neovascularization. The disruptions and some inflammation are seen at the implantation site 
(Figure 4.8F), and no effect on the tissue is observed in the distal half of the eye (Figure 4.8A, 
B). No global inflammatory response was observed, which agrees with previous studies using 
PCL devices in the eye [17]. 
Figure 4.7 Cumulative IOP reduction represented as the area under the curve (AUC) of 
baseline subtracted IOP values of drug-loaded device treated eyes (n=4), empty-device 
treated eyes (n=4), and their contralateral control eyes (n=8) over 91 days. 
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4.5 Discussion  
Poor patient compliance is a well-documented problem with topical glaucoma therapies. 
Sustained-delivery formulations of glaucoma medication represent an unmet need in the field, 
particularly the simultaneous delivery of multiple hypotensive agents. Here, we report the 
development of a polymeric intracameral ocular implant for simultaneous sustained delivery of 
both timolol maleate and brimonidine tartrate. 
According to pharmacokinetics analysis, the amount of drug in the contralateral eye and 
the plasma is below quantifiable limits of LC-MS/MS (<1 ng/mL). This is expected because the 
Figure 4.8 Histological images of the rabbit normal cornea 
(A) and normal angle (B) in the anterior segment of the OS 
eye. Images of the anterior segment showing examples of 
corneal neovascularization (C), fibrous metaplasia shown by 
thickening of the endothelium (D) iris synechia (E) and 
lymphocytes in the posterior stroma signaling focal 
inflammation (F). 
102 
 
implantation site in the anterior chamber is not connected to the nasolacrimal duct, the typical 
route for systemic drug absorption. This allows our device to avoid systemic toxicities associated 
with topical beta blocker application [18]. Assuming a simple one-compartment model with a 
fixed release source and one route of elimination, the steady state concentration 𝑪𝑪𝑺𝑺𝑺𝑺 of each drug 
can be estimated from the half-life of each drug using the following two equations 
 
𝒌𝒌𝒆𝒆 = 𝒍𝒍𝒍𝒍(𝟐𝟐)𝒕𝒕𝒉𝒉𝒉𝒉𝒍𝒍𝒇𝒇−𝒍𝒍𝒍𝒍𝒇𝒇𝒆𝒆 ,𝑪𝑪𝑺𝑺𝑺𝑺 =  𝑹𝑹𝒍𝒍𝒍𝒍𝒌𝒌𝒆𝒆 𝑽𝑽  
where 𝒌𝒌𝒆𝒆 is the elimination rate constant, 𝑹𝑹𝒍𝒍𝒍𝒍 is the release rate from the device, 𝒕𝒕𝒉𝒉𝒉𝒉𝒍𝒍𝒇𝒇−𝒍𝒍𝒍𝒍𝒇𝒇𝒆𝒆 is the 
half-life of each drug in the aqueous humor and V is the volume of the aqueous humor assuming 
the drug is distributed across the entire volume. The steady state concentration of timolol 
concentration in the aqueous humor was calculated to be 323.8 ng/ml based on its half-life of 60 
min [19] and assuming a fixed release source at the measured in vitro release rate of 1.75 μg/ml 
and an aqueous humor volume of 0.325 ml [20]. Our measured aqueous humor concentration is 
on the same order of magnitude, but is approximately 3-fold lower, suggesting that the in vivo 
release rate of timolol from the device might be slightly slower than in vitro. However, this 
concentration is consistent with the aqueous humor concentration measured after 18 h of 
administering a single dose of topical 0.5% timolol to human patients which was reported to be 
105.5 ± 60.9 ng/ml [21]. Based on a study of beta receptor binding activity of timolol in the 
aqueous humor, the measured timolol concentration of approximately 100 ng/ml in the aqueous 
humor would result in 99% beta1 receptor occupancy [21].  
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Based on the half-life of brimonidine in the aqueous humor of 34 min [22], and the in 
vitro release rate of 0.48 μg/day, the expected in vivo steady state concentration in the aqueous 
humor is 50.2 ng/ml. The measured concentrations in the aqueous humor and ICB are an order of 
magnitude lower than anticipated based on the in vitro release rate. Upon examining the devices 
at week 13 we noticed that little to no brimonidine powder was visible in the devices. Based on 
the amount loaded (approximately 1 mg) and their release rate pre-implantation, we anticipated 
the drug release from the devices to last for a substantially longer period of time. This suggests 
that 1) the in vivo release rate of brimonidine may be higher than the measured rate in vitro, 
leading to faster depletion of the device reservoir, and 2) there are modes of clearance in addition 
to the outflow of aqueous humor, such as degradation, that might be contributing to the low 
tissue concentrations  
The return to baseline IOP starting at day 56 may be due to the lowered brimonidine 
concentrations measured in the tissues. However, even with the low brimonidine concentrations 
(under 10 ng/mL) in the aqueous humor and ICB, we were able to achieve statistically significant 
cumulative IOP reductions at earlier time points. We achieved a maximum IOP drop of 5.5 ± 2.8 
mmHg at day 14, which corresponds to a 47% reduction from baseline. According to the FDA 
approval letter [22], brimonidine tartrate ophthalmic solution 0.1% resulted in a maximum of 
29% reduction in IOP after 3 hours in male albino New Zealand rabbits. It is important to note 
that there is less room for IOP reduction in normotensive rabbits compared to rabbits with 
congenitally elevated IOP.  
The histological analysis shows that there was no global inflammation in the eye. All 
abnormalities observed are local to the device implantation site. Given the small dimensions of 
the rabbit eye relative to the human eye (25% relative volume) [23] the device size was 
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associated with iris and corneal contact in the confines of the small anterior chamber. However, 
the current device geometry can be redesigned to further improve biocompatibility. One aspect 
of the geometry was the two-armed, V-shaped design. We observed that the two arms of the 
device did not remain folded, and instead opened up within the eye into a wider V-shape, 
pushing against the corneal epithelium and the iris. This created mechanical pressure that 
explains the observed damage in those tissues. Future goals include reconfiguring and further 
miniaturizing the co-delivery devices to further improve biocompatibility.  
Taken together, we have demonstrated that our polymer thin-film intracameral implant 
device can achieve controlled release of two different hypotensive agents at different release 
rates. The device achieved a statistically significant reduction of cumulative IOP over 13-weeks 
in normotensive rabbits. Timolol maleate concentration in the target tissue was maintained for 13 
weeks. While the in vivo release rate of brimonidine was lower than expected, the low 
concentrations still achieved significant IOP drop. Further optimization of brimonidine 
formulation and/or device size can increase the in vivo release rate and duration of brimonidine 
through the thin-film device. This study demonstrates that the prototype device has the potential 
to achieve sustained-release of two hypotensive agents for glaucoma therapy.  
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Conclusions and Outlook 
The work presented in this dissertation illustrates the diversity of research in the 
interdisciplinary field of biomaterials. Drawing upon techniques in polymer chemistry, 
electrochemistry, drug delivery, and tissue engineering, many engineering and biological 
approaches were involved in the design of two distinct biomaterials for eliciting desired 
therapeutic responses. The results and opportunities provided by these studies have the potential 
to benefit researchers, clinicians, and patients.  
 
5.1 Titania nanotube coatings  
Titania nanotube topography has several advantages as an approach for attenuating 
restenosis. The anodization process is scalable and compatible with metallic substrates, the 
surface modification does not affect bulk mechanical properties, and it avoids the use of the toxic 
drugs commonly used in DES. By better understanding the interactions between titania 
nanotubes and vascular cells, this study can contribute to the further development of an anti-
restenotic surface coating for bare metal stents This study elucidated the effects of nanotube 
topography on a cellular level. The results of this study illustrated that titania nanotube 
topography decreases SMC surface coverage and decreases both EC and SMC response to 
inflammation as compared to flat titania surfaces. Further, 90 nm diameter nanotube geometry 
led to a greater extent cellular response compared to 30 nm or 50 nm diameter nanotubes. 
This work contributes to the understanding of the interactions between titania nanotubes and 
vascular cells on a cellular level, and setting the stage for further mechanistic investigation on a 
molecular level. For example, it would be interesting to further probe the pathways that are 
downstream from FAK, including Rho/ROCK/MLCK, and YAP/Taz, to dissect how the 
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topographical cues of the titania nanotube is transduced as cellular signals that lead to the 
observed phenotype changes. It would be especially interesting to probe how the interactions 
with titania nanotubes affects integrin binding and clustering, and any crosstalk with growth 
factor and cytokine receptor signaling.  
 
5.2 Ocular drug delivery  
This study demonstrated proof-of-concept for a PCL thin-film device for the sustained 
delivery of hypotensive agents without the need for patient input. PCL film-thickness was tuned 
independently for each compartment to achieve desired release rates of for timolol maleate and 
brimonidine tartrate respectively. The device also achieved sustained drug concentrations locally 
in ocular tissues in vivo, with undetectable drug concentrations in systemic circulation. We also 
observed a decrease in intraocular pressure in a normotensive rabbit model, demonstrating that 
the device can achieve a therapeutic response.  
The device design and results also provide opportunities for further optimization and 
refinement. First, the v-shaped design caused the device to open, which sometimes led to 
mechanical disruption of the corneal epithelium and the iris. An alternative design can be 
considered to further improve device biocompatibility, such as by annealing the open ends of the 
device to form a seal and lessen device movement. Another strategy to avoid device contact with 
the delicate structures in the front of the eye is to consider an alternative implantation site in the 
posterior chamber of the eye. In addition, optimization of manufacturing methods has the 
opportunity to lead to increased consistency and further miniaturization of the device. All in all, 
this study demonstrated that film thickness can be tuned to achieve distinct desired release rates 
for two different hypotensive agents. Similar strategies can be applied to other drugs for 
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alternative mono- or combination therapies for the long-term treatment of glaucoma or other 
intraocular diseases.  
Scientists working on the development of biomaterials have the opportunity to draw from a 
diverse array of engineering, biological, and clinical tools to develop technologies that have 
therapeutic potential. The work presented in this dissertation demonstrate the application of 
biomaterials science for addressing persisting clinical needs in the ocular and cardiovascular 
field. The interdisciplinary and creative nature of this field is exciting and enabling. It is my hope 
that this work can contribute to advancing the development of biomaterials for medical 
applications.  
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